US 20070092505A1

(19) **United States**

(12) **Patent Application Publication** (10) **Pub. No.: US 2007/0092505 A1**

Buelow et al. (43) **Pub. Date: Apr. 26, 2007**

(54) **PRODUCTION OF HUMANIZED ANTIBODIES IN TRANSGENIC ANIMALS**

(76) Inventors: **Roland Buelow**, Palo Alto, CA (US); **Josef Platzer**, Muenchen (DE); **Wim van Schooten**, Sunnyvale, CA (US); **Jens-Ulrich Buelow**, Karlsruhe (DE)

Correspondence Address:
HELLER EHRMAN LLP
275 MIDDLEFIELD ROAD
MENLO PARK, CA 94025-3506 (US)

(21) Appl. No.: **11/584,187**

(22) Filed: **Oct. 20, 2006**

Related U.S. Application Data

(62) Division of application No. 09/921,819, filed on Aug. 3, 2001, now Pat. No. 7,129,084.

(60) Provisional application No. 60/222,872, filed on Aug. 3, 2000. Provisional application No. 60/276,156, filed on Mar. 15, 2001.

Publication Classification

(51) **Int. Cl.**
A61K 39/395 (2006.01)
C07K 16/44 (2006.01)

(52) **U.S. Cl.** **424/133.1**; 530/388.15

(57) **ABSTRACT**

This invention relates to humanized antibodies and antibody preparations produced from transgenic non-human animals. The non-human animals are genetically engineered to contain one or more humanized immunoglobulin loci which are capable of undergoing gene rearrangement and gene conversion in the transgenic non-human animals to produce diversified humanized immunoglobulins. The present invention further relates to novel sequences, recombination vectors and transgenic vectors useful for making these transgenic animals. The humanized antibodies of the present invention have minimal immunogenicity to humans and are appropriate for use in the therapeutic treatment of human subjects.

```
          1                                                        50
clone11   [redacted]CACGA AACTTTACGG
 clone3   [redacted]CACGA GGCCCTGCAC
 clone5   [redacted]CACGA GGCCCTGCAC

          151                                                     200
clone11   AATCACTACA AAGAGAAGTC CACCTCGAGG TCTCCGGGTA AATGAGCCTC
 clone3   AATCACTACA CGCAGAAGTC CACCTCTAAG TCTGCGGGTA AATGAGCCTC
 clone5   AATCACTACA CGCAGAAGTC CACCTCTAAG TCTGCGGGTA AATGAGCCTC

          201                                                     250
clone11   GCGCCGCTGA TCTAGTGGAC GTTCCCTCAT CCACCCACCC CTCCCCCCAC
 clone3   ACGTCCCTGC ACCAGCAAGC CCTCACCCAG C..........  ..CCACCCTC
 clone5   ACGTCCCTGC ACCAGCAAGC CCTCACCCAG C..........  ..CCACCCTC

          251                                                     300
clone11   CCCGGGCTCC AGGTCCAGCC AGGGCGCCCT AGCCCCTCCC TGTGTGCATT
 clone3   CCCGGGCTCC AAGTCCAGCC AGGACGCCCT AGCCCCTCCC TGTGTGCATT
 clone5   CCCGGGCTCC AGGTCCAGCC AGGACGCCCT AGCCCCTCCC TGTGTGCATT

          301                                                     350
clone11   CCTCCTGGGC CGCCGTGAAT AAAGCACCCA GGCCGCCCTG GGACCCTGCA
 clone3   CCTCCTGGGC CGCCGTGAAT AAAGCACCCA GGCCACCCTG GGACCCTGCA
 clone5   CCTCCTGGGC CGCCGTGAAT AAAGCACCCA GGCCGCCCTG GGACCCTGCA

          351                                                     400
clone11   ACGCTGTGCT GGTTCTTTCC GAGGCAGAGC CCTGGTGGCC GCCAGGCCTG
 clone3   ACGCTGTGCT GGTTCTTTCC GAGGCAGAGC CCTGGTGGCC GCCAGGCCTG
 clone5   ACGCTGTGCT GGTTCTTTCC GAGGCAGAGC CCTGGTGGCC GCCAGGCCTG

          401                                                     450
clone11   CGGGGGTGGG CTGAGCCGAC TCTGGGCCAC TTTGTTCAGC ATCTGTGGGG
 clone3   CAGGGGTGGG CTGAGCCGAC TCTGGGCCAC TTTGTTCAGC ATCTGTGGGG
 clone5   CGGGGGTGGG CTGAGCCGAC TCTGGGCCAC TTTGTTCAGC ATCTGTGGGG

          451                                                     500
clone11   GAGCTGACCC CACTCCGGGC CAGACACACA GTGAGTGGGT CCAGCAGGCC
 clone3   GAGCTGACCC CGCTCCGGGC CAGACACACA GTGAGTGGGT CCAGCAGGCC
 clone5   GAGCTGACCC CACTCCGGGC CAGACACACA GTGAGTGGGT CCAGCAGGCC

          501                                                     550
clone11   ACCTGGGGGC TGCCCAAGGC CACAGAGGGG CTTGGCCAGA GGCACAGCTC
 clone3   ACCTGGGGGC TGCCCGAGGC CACGGAGGGG CTTGGCCAGA GGCGTACCTC
 clone5   ACCTGGGGGC TGCCCAAGGC CACAGAGGGG CTTGGCCAGA GGCACAGCTC
```

Figure 1(a)

```
          551                                                        600
clone11   CACGGTCCCC TCCAGCCACC ACCTGCTGGG CCGGCCTCTG GACAGGAACC
 clone3   CACGGCCCCC TCCAGCCACC ACCTGCTGGG CCGGCCTCTG GACAGGAACC
 clone5   CACGGTCCCC TCCAGCCACC ACCTGCTGGG CCGGCCTCTG GACAGGAACC

          601                                                        650
clone11   GGGGAAGCCC CCGAGACCCT CAGGGATTGA GGCCCAATGC TTCCCGCCTC
 clone3   GGGGAAGCCC CCGAGACCCT CAGGGATTGA GGCCCAATGC TTCCCGCCTC
 clone5   GGGGAAGCCC CCGAGACCCT CAGGGATTGA GGCCCAATGC TTCCCGCCTC

          651                                                        700
clone11   TGCTCCAGCC CACGCTGTGG GGCAGGGCCA CATCCTTGTC CCCAGGCCCC
 clone3   TGCTCCAGCC CACGCTGTGG GGCAGGGCCA CATCCTTGTC CCCAGGCCCC
 clone5   TGCTCCAGCC CACGCTGTGG GGCAGGGCCA CATCCTTGTC CCCAGGCCCC

          701                                                        750
clone11   TGTCCTTGGG TGTCCAGAGT CCTTGTGTCC ACTCTGGGCC TGCCTGGAGC
 clone3   TGTCCCTGGG TGCCCAGAGT CCTTGTGTCC ACTCTGGGCC TGCCTGGAGC
 clone5   TGTCCTTGGG TGTCCAGAGT CCTTGTGTCC ACTCTGGGCC TGCCTGGAGC

          751                                                        800
clone11   CACGCATGGC CAGGGGGTGG CCCTGCTTCA CCCTCAGGCT CCCAAGGTCA
 clone3   CACGCGTGGC CGGGGGATGG CCCTGCTCCA CCCTCAGGCT CCCAAGGTCA
 clone5   CACGCATGGC CAGGGGGTGG CCCTGCTTCA CCCTCAGGCT CCCAAGGTCA

          801                                                        850
clone11   GGCCTCGCCC TCCCTCGGCC AGGAGGCTCT GCCCGGCTCT CCCTGCCCAG
 clone3   GGCCTCGCCC TCCCTCAGCC AGGAGGCTCT GCCCGGCTCT CCCTGCCCAG
 clone5   GGCCTCGCCC TCCCTCGGCC AGGAGGCTCT GCCCGGCTCT CCCTGCCCAG

          851                                                        900
clone11   GGCCAGGCCT GTGCGCCCAT GGGGAGGTCA TCCCTGTGCC TGAAAGGGGT
 clone3   GGCCAGGCCT GTGCGCCCAT GGGGAGGTCA TCCCTGTGCC TGAAAGGGCT
 clone5   GGCCAGGCCT GTGCGCCCAT GGGGAGGTCA TCCCTGTGCC TGAAAGGGGT

          901                                                        950
clone11   CCAGGCCGAG AGCCCTGAAT GTCCAGGGCA GGGACCTAGC TGCTCCCTGT
 clone3   CCAGGCCGGG AGCCCTGAAT GTCCAGGGCA GGGACCTAGC TGCTCCCTGC
 clone5   CCAGGCCGAG AGCCCTGAAT GTCCAGGGCA GGGACCTAGC TGCTCCCTGT

          951                                                       1000
clone11   GGACACGGAG CCCAGAGCCA CAGACAACAA GCCCCAGCCC CGCACGCACA
 clone3   AGACACGGAG CCCAGAGCCA CAGACAACAA GCCCCAGCCC CGCACGCACA
 clone5   GGACACGGAG CCCAGAGCCA CAGACAACAA GCCCCAGCCC CGCACGCACA

          1001                                                      1050
clone11   CGAGACAGCC CGCACCCAGC CTCCTCCACA CGCACTCAGG TGTACATGCG
 clone3   CAAGACAGCC CGCACCCAGC CTCCTCCACA CGCACTCAGG TGTGCATCCG
 clone5   CGAGACAGCC CACACCCCGC CTCCTCCACA CGCACTCAGG TGTGCATCCG
```

Figure 1(b)

```
          1051                                                    1100
clone11   CACATGAGCA CACTTCACCC CGTCACACCC ACACACCTAC ACACACTCAG
 clone3   CACATGAGCA CACTTCACCC CGTCACACCC ACACGCCTAC ACACACTCAG
 clone5   CACATGAGCA CACTTCACCC CATCACACCC ACACGCCTAC ACACACTCAG

          1101                                                    1150
clone11   GTCTCGCACT CGGGGACCCA TGGGGTGACC CCACGGGCCC AGA.CCAGAG
 clone3   GTCTCGCACT CGGGGACCCA TGGGGTGACC CCACAGGCCC AGACCCAGAG
 clone5   GTCTCGCACT CGGGGACCCA TGGGGTGACC CCACAGGCCC AGACCCAGAG

          1151                                                    1200
clone11   CTGGGTCTTG TGAGCCCTCC CTGTGGACAC CAGCTGGGCC CCACCCTCCA
 clone3   CTGGGTCTTG TGAGCCCTCC CTGTGGACAC CAGCTGGTCC CCACCCTCCA
 clone5   CTGGGTCTTG TGAGCCCTCC CTGTGGACAC CAGCTGGTCC CCACCCTCCA

          1201                                                    1250
clone11   GCGCCCATGG GCTGCTCAGC GGCCCTTTCC CACACTGACC ACACTGACCA
 clone3   GCGCCCATGG GCTGCTCAGT GGCCCTTTCC CACACTGACC ACACTGACCA
 clone5   GCGCCCGTGG GCTGCTCAGC GGTCCTTTCC CACACTGACC ACACTGACCA

          1251                                                    1300
clone11   GGTCAGACAT CCGTTCCTTG CCTCCCCTGG GACACCCACG CCCCTCCCTA
 clone3   GGTCAGACAT CCGTTCCTTG CCTCCCCTGG GGCACCCACG CCCCTCCCTA
 clone5   GGTCAGACAT CCGTTCCTTG CCTCCCCTGG GGCACCCATG CCCCTCCCTA

          1301                                                    1350
clone11   GCAGGCTGAG ATCCCCCCTC AGCCCCTCGT CCTGGCAGCC TCACCCCTCG
 clone3   GCAGGCTGAG ATCCCCCCTC AGCCCCTCGT CCTGGCACCC TCACCCCTCA
 clone5   GCAGGCTGAG ATCCCCCCTC AGCCCCTCGT CCTGGCACCC TCACCCCTCA

          1351                                                    1400
clone11   GGCACAGCAC CCCTCAGGCC CGGTGCTGTC AGCCCTCCCT CCCCGGGGGC
 clone3   GGCACAGGGA CAC...AGCC CGGCGCTGTC TGCCCTCCCT CCCTGGGGGC
 clone5   GGCACAGGGA CAC...AGCC CGGTGCTGTC TGCCCTCCCT CCCTGGGGGC

          1401                                                    1450
clone11   AGGGCCCAGG AACGTGCGCT CTGCTGACCC TCCCAGCTCC AGGCCTGGCC
 clone3   AGGGCCCAGG CTCACATGCT CTGCTGACCC TCCCGGCTCC AGGCCTGGCC
 clone5   AGGGCCCAGG CTCACATGCT CTGCTGACCC TCCCAGCTCC AGGCCTGGCC

          1451                                                    1500
clone11   CCCAGGGCAG AGGAGGCCAG GAACTGAGCC TCTGTCCTGT GGGGAGGTAG
 clone3   CCCAGGGCAG AGGAGGCCAG GAACTGAGCC TCTGTCCTGG GGGGAGGTGG
 clone5   CCCAGGGCAG AGGAGGCCAG GAACTGAGCC TCTGTCCTGG GGGGAGGTGG

          1501                                                    1550
clone11   GGTCAGGGTC CCAGCTCAGG GCACAGCTCA GGATGGGAGC AGGACCCCAC
 clone3   GGTCAGGGCC CCAGCTCAGG GCACAGCTCA GGATGGGAAC AGGACACCAC
 clone5   GGTCAGGGCC CCAGCTCAGG GCACAGCTCA GGATGGGAGC AGGACACCAC
```

Figure 1(c)

```
          1551                                                      1600
clone11   AGGCCAGGCC CAGATAGCAG CCAGGGCTGG AGGGGTTGGG GCTGGGGCTG
 clone3   AGGCCAGGCC CAGACAGTGG CCAGGGCTGG AGGGGTGGGG TCTGGGGCTG
 clone5   AGGCCAGGCC CAGACAGTGG CCAGGGCTGG AGGGGTGGGG TCTGGGGCTG

          1601                                                      1650
clone11   GGCCCCAGAG ACTGACCTCA GGTGACCCCT GCCTGGCCCA TGGGGAGATC
 clone3   GGGCCCAGAG ACTGACCTCA GGTGATCCCT GCCCAGCCCA TGGGGGGATC
 clone5   GGCCCCAGAG AATGACCTCA GGTGATCCCT GCCCAGCCCA TGGGGGGATC

          1651                                                      1700
clone11   ACGCCACCTT CCCCCCACCC AGAGGGAGCC CTGCCC...T ACCCCAGTGA
 clone3   CTGCCACCTT CCCCCCACCC AGAGGGAGCC CTGCCCCGAG GCCCTGATGA
 clone5   CTGCCACCTT CCCCCCACCC AGAGGGAGCC CTGCCCCGAG GCCCTGATGA

          1701                                                      1750
clone11   CCCTGCCCAG CCCTCCGTGG GCAGACACAG CACTGACCAC CCCTCCCTGT
 clone3   TGCCACCCAG CCCCCCGTGG GCAGACACAG CACTGACCAC CCCTCCCTGT
 clone5   TGCCACCCAG CCCCCCGTGG GCAGACACAG CACTGACCAC CCCTCCCTGT

          1751                                                      1800
clone11   GCAGACTTGC TGCTGGAGGA GGAGATCTGT GCGGACGACC TGGATGGGGA
 clone3   GCAGACCTGC TGCTGGAGGA GGAGATCTGT GCGGACGCCC AGGACGGGGA
 clone5   GCAGACCTGC TGCTGGAGGA GGAGATCTGT GCGGACGCCC AGGACGGGGA

          1801                                                      1850
clone11   GCTGGACGGG CTC[redacted]
 clone3   GCTGGACGGG CTC[redacted]
 clone5   GCTGGACGGG CTC[redacted]
```

Figure 1(d)

```
          101                                                   150
clone11   [redacted] CACGAGGCTC TACACAACCA CTACACACAG
clone1    [redacted] CACGAGGCTC TGCACAACCA CTACACACAG

          151                                                   200
clone11   AAGTCGATCT CTAAGCCTCC GGGTAAATGA GCCACATGCC CCCGCACCAG
clone1    AAGTCGGTCT CTAAGCCTCC GGGTAAATGA GCCACACGCC CCCGCACCAG

          201                                                   250
clone11   CAAGCCCTCA CCCAGCCCGC CCTCCCCGGG CTCCAGGTCC AGCCAGGACG
clone1    CAAGCCCTCA CCCAGCCCGC CCTCCCCGGG CTCCAGGTCC AGCCAGGACG

          251                                                   300
clone11   CCCTAGCCCC TCCCTGTGTG CATGCCTCCT GGGCCGCCAT GAATAAAGCA
clone1    CCCTAGCCCC TCCCTGTGTG CATGCCTCCT GGGCCGCCAT GAATAAAGCA

          301                                                   350
clone11   CCCAGGCCGC CCTGGGACCC TGCAACGCTG TGCTTGTTCT TTCCGAGGCA
clone1    CCCAGGCCGC CCTGGGACCC TGCAGCGCTG TGCTGGTTCT TTCCGAGGCA

          351                                                   400
clone11   GAGCCCTGGT GACCGCCAGG CCTGCGGGGG GTGGGCTGAG CCCACTCTGG
clone1    GAGCCCTGGT GATCGCCAGG CCTGCGGGGG GCGGGCTGAG CCCACTCTGG

          401                                                   450
clone11   GCCGCTTGGT TCAGCATCTG TGGGGGCGCT GACCCCTCTC CGGGCCAGAC
clone1    GCCGCTTGGT TCAGCATCTG TGGGGGCGCT GACCCCTCTC CGGGCCAGAC

          451                                                   500
clone11   ACACAGTGAG TGGGTCCGGC AGGGCACCTG GGGGCTGCCC GAGGCCTCGG
clone1    ACACAGTGAG TGGGTCCGGC AGGGCACCTG GGGGCTGCCC GAGGCCTCGG

          501                                                   550
clone11   AGGGGCTTGG CCAGAGGCGC AGCTTCACGG CCCCCTCCAG CCACCACATT
clone1    AGGGGCTTGG CCAGAGGCGC AGCTCCACGG CCCCCTCCAG CCACCACATT

          551                                                   600
clone11   CTGGGCCAGA CTCTGGGCAG GAACGGGGGA AGCCCCCGAC ACCTCAGGGA
clone1    CTGGGCCAGA CTCTGGGCAG GAACGGGGGA AGCCCCCGAC ACCTCAGGGA

          601                                                   650
clone11   TTGAGGCCCA ACGCTTCCCG CCTCTGCTCC AGCCCACGCT GAGGGGCAGG
clone1    TTGAGGCCCA ACGCTTCCCG CCTCTGCTCC AGCCCACGCT GAGGGGCAGG
```

Figure 2(a)

```
          651                                                        700
clone11   GCCGCGGCCT TGTCCCCAGG CCCCTGTTCC TGGGTGCCCA GAGTCCGTGT
 clone1   GCCGCGGCCT TGTCCCCAGG CCCCTGTTCC TGGGTGCCCA GAGTCCGTGT

          701                                                        750
clone11   GTCCACTCTG GGCCTGCCTG GAGCCAGACT GGCCCAGGGG GAGGCCCTGC
 clone1   GTCCACTCTG GGCCTGCCTG GAGCCAGACT GGCCCAGGGG GAGGCCCTGC

          751                                                        800
clone11   TTCACCCTCA GGCTCCCGAG GTCAGGCATC ATCCTCGTCG GCCAGTAGCT
 clone1   TTCACCCTCA GGCTCCCGAG GTCAGGCATC ATCCTCGTCG GCCAGTAGCT

          801                                                        850
clone11   CTGCCTGGCT CTCTCTGCCC GGGGCCAAGC CTGTGTGCCC ATGGGGAGGT
 clone1   CTGCCTGGCT CTCTCTGCCC GGGGCCAAGC CTGTGTGCCC ATGGGGAGGT

          851                                                        900
clone11   CGTCCCTGTG CCTGAAAAGG GCCCAGGCTG GGAGCCCTGA ACGTCCAGGG
 clone1   CGTCCCTGTG CCTGAAAAGG GCCCAGGCTG GGAGCCCTGA ACGTCCAGGG

          901                                                        950
clone11   CAGGGACCTA GCTGCTCCCT GGGGACACTG AGCCCAGAGC CCCAGACACC
 clone1   CAGGGACCTA GCTGCTCCCT GGGGACACTG AGCCCAGAGC CCCAGACACC

          951                                                       1000
clone11   AAGCCCCAGC CCCGCACGCA CACGAGACAG CCCACACCCA GCGTCCTCCA
 clone1   AAGCCCCAGC CCCGCACGCA CACGAGACAG CCCACACCCA GCGTCCTCCA

          1001                                                      1050
clone11   CACGCACTCA GGCGTCCACC CGCACACAAG CATGCTTCAC CCCCGTCACA
 clone1   CACCCACTCA GGCGTCCACC CGCACACAAG CATGCTTCAC CCCCGTCACA

          1051                                                      1100
clone11   CACCCACATG CCTGCACACA CTCAGGTCTC ACGCTCCGGG ACCCATGGAG
 clone1   CACCCACATG CCTGCACACA CTCAGGTCTC ACGCTCCGGG ACCCATGGAG

          1101                                                      1150
clone11   TGATCCCACG GGCCCAGACC CAGAGCTGGG TCTCATGAGC CCTCCCTGTG
 clone1   TGATCCCACG GGCCCAGACC CAGAGCTGGG TCTCATGAGC CCTCCCTGTG

          1151                                                      1200
clone11   GACACCAGCT GGTCCCCATT CTCCAGCGCC CTTGGGCTGC TCAGTGGCCC
 clone1   GACACCAGCT GGTCCCCATC CTCCAGCGCC CTTGGGCTGC TCAGTGGCCC

          1201                                                      1250
clone11   TTTCCCACAC TGACCACACT GACCAGGTCA GACATCCTTC CTCGCCTCCC
 clone1   TTTCCCACAC TGACCACACT GACCAGGTCA GACATCCTTC CTCGCCTCCC
```

Figure 2(b)

```
          1251                                                    1300
clone11   CTGGGGCACC CACGCCCCTC CCTCGCAGGC TGAGACCCCC CCTCAGCCCC
clone1    CTGGGGCACC CACGCCCCTC CCTTGCAGGC TGAGACCCCC CCTCAGCCCC

          1301                                                    1350
clone11   TCGTCCTGGC ACCCTCACCC CTCGGGCACA GGGACACAGC CCGGCACTGT
clone1    TCGTCCTGGC ACCCTCACCC CTCGGGCACA GGGACACAGC CCGGCACTGT

          1351                                                    1400
clone11   CTGCCCTCCC TCTCGGGGAC AGAGCCCAGG CACGTGTGCT CTGCTGAGCC
clone1    CTGCCCTCCC TCTCGGGGAC AGAGCCCAGG CACGTGTGCT CTGCTGAGCC

          1401                                                    1450
clone11   TCCCGGCTCC AGGCCTGGCC CCCAGGGCAG AGGAGGCCAG GAATTGAGCC
clone1    TCCCGGCTCC AGGCCTGGCC CCCAGGGCAG AGGAGGCCAG GAATTGAGCC

          1451                                                    1500
clone11   TCTGTCCTGC GGGGAGGTGG GGTCAGGGCC CCAGCTCAGG GCACAGCTCA
clone1    TCTGTCCTGC GGGGAGGTGG GGTCAGGGCC CCAGCTCAGG GCACAGCTCA

          1501                                                    1550
clone11   GGATGGGAGC AGGACCCCAC AGGCCAGGCC CAGACAGTGG CCAGGGCTGG
clone1    GGATGGGAGC AGGACCCCAC AGGCCAGGCC CAGACAGTGG CCAGGGCTGG

          1551                                                    1600
clone11   GGCTGGGGCT GGGGCCCAGA GACTGACCTC AGGTGACCCC TGCCCGGCCC
clone1    GGCTGGGGCT GGGGCCCAGA GACTGACCTC AGGTGACCCC TGCCCGGCCC

          1601                                                    1650
clone11   ATGGGGGATC ACACCGCCAT CCCCCCCGCC GCAGAGGGAG CCCTGCCCCG
clone1    ATGGGGGATC ACACCGCCAT CCCCCCCGCC GCAGAGGGAG CCCTGCCCCG

          1651                                                    1700
clone11   AAGCCCCGAT GGCCCCGCCC AGCCCCCCGT GGGCAGACAC AGCACTGACC
clone1    AAGCCCCGAT GGCCCCGCCC AGCCCCCCGT GGGCAGACAC AGCACTGACC

          1701                                                    1750
clone11   CCCCTCCCTG TGCAGATCTG CTGCTGGAGG AGGAGAGCTG TGCGGACGCC
clone1    CCCCTCCCTG TGCAGATCTG CTGCTGGAGG AGGAGAGCTG TGCGGACGCC

          1751                                                    1800
clone11   CAGGACGGGG AGCTGGACGG GCTCTGGACG ACTATCTCCA TCTTCATCAC
clone1    CAGGACGGGG AGCTGGACGG GCTCTGGACG ACTATCTCCA TCTTCATCAC

          1801                                                    1850
clone11   GCCCTTCCTG CTCAGCGTCT GCTACAGCGC CACCGTGACC CTCTTCAAGG
clone1    GCTCTTCCTG CTCAGCGTCT GCTACAGTGC CACCGTGACC CTCTTCAAGG
```

Figure 2(c)

```
          1851                                                    1900
clone11   TGGGGGTCCA CCCTGCTGGG CCCTCGGGCC CCCTCTCTGT CCCCAGGGTC
 clone1   TGGGGGCCCA CCCTGCTGGG CCCTCGGGCC CCCTCTCTGT CCCCAGGGTC

          1901                                                    1950
clone11   CCCGCAGAGT CCCTCCCTGC CCCTCACTGT CCCTCCCTGT CCCTCTCTGT
 clone1   CCCGCAGAGT CCCTCCCTGC CCCTCACTGT CCCTCCCTGT CCCTCTCTGT

          1951                                                    2000
clone11   CCCTCTCTGT CCCTCTCTGT CCCTCTCTGT CCGTTCATTT TCCCTTCACC
 clone1   CCCTCTCTGT CCCTCTCTGT CCCTCTCTGT CCGCTCATTT TCCCTTCACC

          2001                                                    2050
clone11   GTAAGCTTGA GACAGATTGG GGTCATTTCA GAGGGCGTCT GAAGAGTCTC
 clone1   GTAAGCTTGA GACAGATTGG GGTCATTTCA GAGGGCGTCT GAAGAGTCTC

          2051                                                    2100
clone11   TGTGCCGCAC GCCTCCCTTC ATGTCAGTGG GGAGAATTCA GCAAGGGTGG
 clone1   TGTGCCGCAC GCCTCCCTTC ATGTCAGTGG GGAGAATTCA GCAAGGGTGG

          2101                                                    2150
clone11   AGTGCTGGGT GAGAAATGAG GCTTGCGGCG CTCACGAGCA GTGATGGGGC
 clone1   AGTGCTGGGT GAGAAATGAG GCTTGCGGCG CTCACGAGCA GTGATGGGGC

          2151                                                    2200
clone11   ACTGCTGCTC CCTGAGACCT GCGCGGACAC CGTTTTCCAT CGCAGGAGAA
 clone1   ACTGCTGCTC CCTGAGACCT GCGCGGACAC CGTTTTCCAT CGCAGGAGAA

          2201                                                    2250
clone11   GCGGGCAAGG GAAAACGCCC TCTTGGTCTC TCTTGAGTAA ATGTCGCGTT
 clone1   GCGGGCAAGG GAAAACGCCC TCTTGGTCTC TCTTGAGTAA ATGTCGCGTT

          2251                                                    2300
clone11   TTGGTCATCA GTCCCTCCCC CAGTGAGGCT AGAGGAGTTT ACTTCTCCCT
 clone1   TTGGTCATCA GTCCCTCCCC CAGTGAGGCT AGAGGAGTTT ACTTCTCCCT

          2301                                                    2350
clone11   CTCGATGGTC AGGTCAGGAC TGTCATAGAC TCCGGATCAC CTTCCTGTAA
 clone1   CTCGATGGTC AGGTCAGGAC TGTCATAGAC TCCGGATCAC CTTCCTGTAA

          2351                                                    2400
clone11   ATGCTTGCTT TTTGTGTGCA GAGAGCCTGT TTTAGCTCGG GGGTCCTCAG
 clone1   ATGCTTGCTT TTTGTGTGC. .AGAGCCTGT TTTAGCTCGG GGGTCCTCAG

          2401                                                    2450
clone11   CTCACTGAGC TCGCGGGGCA GGGGTGGGCT CGGGCTGGCG CCGCCTGTTC
 clone1   CTCACTGAGC TCGCGGGGCA GGGGTGGGCT CGGGCTGGCG CCGCCTGTTC
```

Figure 2(d)

```
          2451                                                  2500
clone11   GGGAGCGCAT CTCCAGCATG CTGTCGCACA GCTTCGTTGC TAACAAGACC
 clone1   GGGAGCGGCA TCTCCAGCTG CTGTCGCACA GCTTCGTTGC TAACAAGACC

          2501                                                  2550
clone11   GCTTAGTCTC GTGGTTAGAC CAACCTGCTT TCTCGAGTAA TTGTTAATTT
 clone1   GCTTAGTCTC GTGGTTAGAC CAACCTGCTT TCTCGAGTAA TTGTTAATTT

          2551                                                  2600
clone11   ACAGGAGTTT CCTGTATTTT TCAACTTATA ATCCCCTAGT CAGATAACTC
 clone1   ACAGGAGTTT CCTGTATTTT TCAACTTATA ATCCCCTAGT CAGATAACTC

          2601                                                  2650
clone11   TTTAATCACC TATTCTGCCC CTTCATTTTC TCCCTATCGA TCTCAGCAAC
 clone1   TTTAATCACC TATTCTGCCC CTTCATTTTC TCCCTATCGA TCTCAGCAAC

          2651                                                  2700
clone11   CCATCACTGC CCTCACTGTC CTTAAACTGT CCCTTAACTG ACCAGACTGT
 clone1   CCATCACTGC CCTCACTGTC CTTAAACTGT CCCTTAACTG ACCAGACTGT

          2701                                                  2750
clone11   CCCTCAGTGT CCCCTCAGAG TCACCTCCCT ATCACCTCAC TGTCCCTCTC
 clone1   CCCTCAGTGT CCCCTCAGAG TCACCTCCCT ATCACCTCAC TGTCCCTCTC

          2751                                                  2800
clone11   TGCCCCTCTC TGCCCCTCTC TGTCCCTCCC TGCCCCTCCC CGTCCCCTCT
 clone1   TGCCCCTCTC TGCCCCTCTC TGTCCCTCTC TGTCCCTCCC CGTCCCCTCT

          2801                                                  2850
clone11   CTGTCCCTCT CTGCCCCTCA CTGCTCCTCT CTGCACCTCA CTGCTCCTCA
 clone1   CTGTCCCTCT CTGCCCCTCA CTGCTCCTCT CTGCACCTCA CTGCTCCTCA

          2851                                                  2900
clone11   CTGCCCTGGG GGAGGCCCGC ATCGAGGTGT CTCTGCTCAC CCCGTCCCCC
 clone1   CTGCCCTGGG GGAGGCCCGC ATCGAGGTGT CTCTGCTCAC CCCGTCCCCC

          2901                                                  2950
clone11   ACCCCGTACC CCCCGCCAGG [redacted]
 clone1   ACCCCGTCCC CCCCGCCAGG [redacted]
```

Figure 2(e)


NotI
2.8kb
5'Ck
EcoRI
SalI
1.3kb
BamHI
0.5kb
SalI
0.5kb
huCk
KpNI
2.6kb
3'Ck
Lox71 neo Lox66
XhoI blunt/
XhoI blunt
BamHI
EcoRI
0.2kb
2.5 kb
Hsv-Tk
EcoRI
BamHI blunt/
XhoI blunt

Figure 7a


XhoI
EcoRI
2.5 kb
Hsv-Tk
EcoRI
0.2kb
XhoI
3.1 kb
3'Cg
KpNI
1.8kb
HuCg1
BamHI
SalI
0.5kb
Lox71 neo Lox66
EcoRI
SalI
1.3kb
1.9 kb
5'Cg
NotI

Figure 7b

Figure 8.

tgacctacct accctgccaa ggtcaggggt cctccaaggc
aagggatcac atggcaccac ctctcttgca gcctccacca agggcccatc ggtcttcccc
ctggcaccct cctccaagag cacctctggg ggcacagcgg ccctgggctg cctggtcaag
gactacttcc ccgaaccggt gacggtgtcg tggaactcag gcgccctgac cagcggcgtg
cacaccttcc cggctgtcct acagtcctca ggactctact ccctcagcag cgtggtgacc
gtgccctcca gcagcttggg cacccagacc tacatctgca acgtgaatca caagcccagc
aacaccaagg tggacaagaa agttggtgag aggccagcac agggagggag ggtgtctgct
ggaagccagg ctcagcgctc ctgcctggac gcatcccggc tatgcagccc cagtccaggg
cagcaaggca ggccccgtct gcctcttcac ccggaggcct ctgcccgccc cactcatgct
cagggagagg gtcttctggc tttttcccca ggctctgggc aggcacaggc taggtgcccc
taacccaggc cctgcacaca aaggggcagg tgctgggctc agacctgcca agagccatat
ccgggaggac cctgcccctg acctaagccc accccaaagg ccaaactctc cactccctca
gctcggacac cttctctcct cccagattcc agtaactccc aatcttctct ctgcagagcc
caaatcttgt gacaaaactc acacatgccc accgtgccca ggtaagccag cccaggcctc
gccctccagc tcaaggcggg acaggtgccc tagagtagcc tgcatccagg gacaggcccc
agccgggtgc tgacacgtcc acctccatct cttcctcagc acctgaactc ctgggggggac
cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc cggacccctg
aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag ttcaactggt
acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag cagtacaaca
gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg aatggcaagg
agtacaagtg caaggtctcc aacaaagccc tcccagcccc catcgagaaa accatctcca
aagccaaagg tgggacccgt ggggtgcgag ggccacatgg acagaggccg gctcggccca
ccctctgccc tgagagtgac cgctgtacca acctctgtcc ctacagggca gccccgagaa
ccacaggtgt acaccctgcc cccatcccgg gatgagctga ccaagaacca ggtcagcctg
acctgcctgg tcaaaggctt ctatcccagc gacatcgccg tggagtggga gagcaatggg
cagccggaga acaactacaa gaccacgcct cccgtgctgg actccgacgg ctccttcttc
ctctacagca agctcaccgt ggacaagagc aggtggcagc aggggaacgt cttctcatgc
tccgtgatgc atgaggctct gcacaaccac tacacgcaga agagcctctc cctgtctccg
ggtaaatgag cgctgtgccg gcgagctgcc cctctccctc ccccccacgc cgcagctgt.

Figure 9.

tgagtgacag tgtcctgacc atgtcgtctg tgtttgcagg tgtccagtgt
gaggtgcagc tgttggagtc cgggggaggt ctcgtccagc cagggggggac cctgagactc
acctgcgcag tctctggatt caccttcagt agctatgcaa tgagctgggt ccgccaggct
ccagggaagg ggctggaatg ggtcggagcc attagtggta gtggtagcac atactacgcg
gacagcgtga aaggccgatt caccatctcc agagacaact ccaagaacac gctgtatctg
caaatgaaca gtctgagagc cgaggacacg gccgcctatt actgtgcgaa agacacagtg
aggggccctc aggctgagcc cagacacaaa cctccctgca

Figure 10.

.catccacat ggcacccagg
ggagatgtcc actggtacct aagcctcgcc atcctgtttg cttctttcct caggaactgt
ggctgcacca tctgtcttca tcttcccgcc atctgatgag cagttgaaat ctggaactgc
ctctgttgtg tgcctgctga ataacttcta tcccagagag gccaaagtac agtggaaggt
ggataacgcc ctccaatcgg gtaactccca ggagagtgtc acagagcagg acagcaagga
cagcacctac agcctcagca gcaccctgac gctgagcaaa gcagactacg agaaacacaa
agtctacgcc tgcgaagtca cccatcaggg cctgagctcg cccgtcacaa agagcttcaa
caggggagag tgttagagcg agacgcctgc cagggcaccg ccagcgaccc tgaggcccag
cctcgc.

Figure 11.

..ggcaggct gctcccaccc
catgcaggag gcagtaccag gcaggaccca gcatggacat gagggtccct gctcagctcc
tgggactcct gctgctctgg ctcccaggta aggagggaaa caacaaaaat tttattcagc
cagtgtagcc actaatgcct ggcacttcag gaaattcttc ttagaacatt actaatcatg
tggatatgtg tttttatgtt cctaatatca gataccagat gttacatcca gatgacccag
tctccatcct ctctgtctgc atctgtggga gacagagtca ccatcacttg ccgagccagt
cagggcatta gcaattactt agcctggtat cagcagaaac cagggaaggt tcccaagctc
ctgatttatg ctgcatccac tttgcaatct ggggtcccat cgcggttcag tggcagtgga
tctgggacag atttcactct taccatcagc agcctgcagc ctgaagatgt tgccacctat
tactgtcaaa agtacaacag tgcccctcca cttttcggcg gagggaccaa ggtggagatc
aaacgtaagt gcactttcct aatgttcctc accgtttctg cctgatttgt ttgctttttc
catttttcgctat..

Figure 12.

catacacag ccatacatac gcgtgtggcc gctctgcctc tctcttgcag gtcagcccaa
ggctgccccc tccgtcactc tgttcccgcc ctcctctgag gagcttcaag ccaacaaggc
cacactggtg tgtctcataa gtgacttcta cccgggagcc gtgacagtgg cttggaaagc
agatagcagc cccgtcaagg cgggagtgga gaccaccaca ccctccaaac aaagcaacaa
caagtacgcg gccagcagct atctgagcct gacgcctgag cagtggaagt cccacagaag
ctacagctgc caggtcacgc atgaagggag caccgtggag aagacagtgg cccctacaga
atgttcatag tagtcccact ggggatgcaa tgtgaggaca gtggttcctc accctccctg

Figure 13.


50bp homology
chicken Cλ
kanR
first exchange by
homologous recombination
mediated by recE/recT
selection with kanamycin
kanR
hum Cλ
second exchange by
homologous recombination
mediated by recE/recT
loss of kanamycin resistance
hum Cλ

Figure 14.

.ttgccgttt tctcccctct ctcctctccc tctccaggtt ccctggtgca gtcagtgctg actcagccgc
cctcggtgtc agcagccccg ggacaagaag tcacgatctc ctgctccggg tctagtagca acattggcga
taatttcgtc tcttggtacC agcagctgcc tggcactgcc cctaagcttc tgatctatga taacaacAag
agaccctcgg gcatccctga ccgattctcc ggttccaaat ccggcacctc agccacatta ggcatcactg
ggctccaaac cggcgacgag gctgactatt actgtgggac ttgggacagc agcctttctg ttggtatgtt
tgggggcggg acacgcgtga ccgtcctagg tgagtcgctg acctcgtctc ggtctttctt cccccat…



Figure 15. Humanized chicken light chain locus.

PRODUCTION OF HUMANIZED ANTIBODIES IN TRANSGENIC ANIMALS

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This is a divisional application claiming the benefit of the priority of copending application Ser. No. 09/921,819, filed Aug. 3, 2001 under 35 U.S.C. 120, which is a non-provisional application filed under 37 CFR 1.53(b), claiming priority under 35 USC 119(e) to Provisional Application Ser. No. 60/222,872, filed on Aug. 3, 2000, and Provisional Application Ser. No. 60/276,156, filed on Mar. 15, 2001, the contents of which are incorporated herein by reference.

FIELD OF INVENTION

[0002] This invention relates to humanized antibodies produced from transgenic non-human animals. The non-human animals are genetically engineered to contain one or more humanized immunoglobulin loci which are capable of undergoing gene rearrangement and gene conversion in the transgenic non-human animals to produce diversified humanized immunoglobulins. The present invention further relates to novel sequences, recombination vectors and transgenic vectors useful for making these transgenic animals. The humanized antibodies of the present invention have minimal immunogenicity to humans and are appropriate for use in the therapeutic treatment of human subjects.

BACKGROUND OF THE INVENTION

[0003] The therapy of infectious diseases caused by bacteria, fungi, virus and parasites is largely based on chemotherapy. However, the emergence of drug-resistant organisms requires the continuous development of new antibiotics. Therapies of patients with malignancies and cancer are also based on chemotherapy. However, many of these therapies are ineffective and the mortality of diseased patients is high. For both infectious diseases and cancer, improved and innovative therapies are needed. Therapy of steroid resistant rejection of transplanted organs requires the use of biological reagents (monoclonal or polyclonal antibody preparations) that reverse the ongoing alloimmune response in the transplant recipient. The major problem of antibody preparations obtained from animals is the intrinsic immunogenicity of non-human immunoglobulins in human patients. In order to reduce the immunogenicity of non-human antibodies, genetic engineering of individual antibody genes in animals has been proposed. In particular, it has been shown that by fusing animal variable (V) region exons with human constant (C) region exons, a chimeric antibody gene can be obtained. However, this approach may only eliminate the immunogenicity caused by the non-human Fc region, while the remaining non-human Fab sequences may still be immunogenic. In another approach, human immunoglobulin genes for both, heavy and light chain immunoglobulins have been introduced into the genome of mice. While this genetic engineering approach resulted in the expression of human immunoglobulin polypeptides in genetically engineered mice, the level of human immunoglobulin expression is low. This may be due to species-specific regulatory elements in the immunoglobulin loci that are necessary for efficient expression of immunoglobulins. As demonstrated in transfected cell lines, regulatory elements present in human immunoglobulin genes may not function properly in non-human animals.

[0004] Several regulatory elements in immunoglobulin genes have been described. Of particular importance are enhancers downstream (3') of heavy chain constant regions and intronic enhancers in light chain genes. In addition, other, yet to be identified, control elements may be present in immunoglobulin genes. Studies in mice have shown that the membrane and cytoplasmic tail of the membrane form of immunoglobulin molecules play an important role in expression levels of human-mouse chimeric antibodies in the serum of mice homozygous for the human Cγ1 gene. Therefore, for the expression of heterologous immunoglobulin genes in animals it is desirable to replace sequences that contain enhancer elements and exons encoding transmembrane (M1 exon) and cytoplasmic tail (M2 exon) with sequences that are normally found in the animal in similar positions.

[0005] The introduction of human immunoglobulin genes into the genome of mice resulted in expression of a diversified human antibody repertoire in genetically engineered mice. In both mice and humans, antibody diversity is generated by gene rearrangement. This process results in the generation of many different recombined V(D)J segments encoding a large number of antibody molecules with different antigen binding sites. However, in other animals, like rabbits, pigs, cows and birds, antibody diversity is generated by a substantially different mechanism called gene conversion. For example, it is well established that in rabbit and chicken, VDJ rearrangement is very limited (almost 90% of immunoglobulin is generated with the 3'proximal VH1 element) and antibody diversity is generated by gene conversion and hypermutation. In contrast, mouse and human gene conversion occurs very rarely, if at all. Therefore, it is expected that in animals that diversify antibodies by gene conversion a genetic engineering approach based on gene rearrangement will result in animals with low antibody titers and limited antibody diversity. Thus, the genetic engineering of large animals for the production of non-immunogenic antibody preparations for human therapy requires alternative genetic engineering strategies.

Relevant Literature

[0006] The use of polyclonal antibody preparations for the treatment of transplant rejection was recently reviewed by N. Bonnefoy-Berard et al., *J Heart Lung Transplant* 1996; 15(5): 435-442; C. Colby et al., *Ann Pharmacother* 1996; 30(10):1164-1174; M. J. Dugan et al., *Ann Hematol* 1997; 75(1-2):41-46. The use of polyclonal antibody therapies for autoimmune diseases has been described by W. Cendrowski, *Boll Ist Sieroter Milan* 1997; 58(4):339-343; L. K. Kastrukoffet al., *Can J Neurol Sci* 1978; 5(2):175-178; J. E. Walker et al., *J Neurol Sci* 1976; 29(24):303-309. The depletion of fat cells using antibody preparations has been described by L. De Clercq et al., *J Anim Sci* 1997; 75(7):1791-1797; J. T. Wright et al., *Obes Res* 1995; 3(3):265-272.

[0007] Regulatory elements in immunoglobulin genes have been described by Bradley et al. (1999), *Transcriptional enhancers and the evolution of the IgH locus*; Lauster, R. et al., *Embo J* 12: 4615-23 (1993); Volgina et al., *J Immunol* 165:6400 (2000); Hole et al., *J Immunol* 146:4377 (1991).

[0008] Antibody diversification by gene conversion in chicken and rabbit has been described by Bucchini et al.,

Nature 326: 409-11 (1987); Knight et al., *Advances in Immunology* 56: 179-218 (1994); Langman et al., *Res Immunol* **144: 422-46** (1993). The generation of mice expressing human-mouse chimeric antibodies has been described by Pluschke et al., *Journal of Immunological Methods* 215: 27-37 (1998). The generation of mice expressing human-mouse chimeric antibodies with mouse derived membrane and cytoplamic tails has been described by Zou et al., *Science* 262: 1271-1274 (1993); Zou et al. *Curr Biol* 4: 1099-1103. The generation of mice expressing human immunoglobulin polypeptides has been described by Bruggemann et al. *Curr Opin Biotechnol* 8(4): 455-8 (1997); Lonberg et al. *Int Rev Immunol* 13(1):65-93 (1995); Neuberger et al., *Nature* 338: 350-2 (1989). Generation of transgenic mice using a BAC clone has been described by Yang et al., *Nat Biotechnol* 15: 859-65 (1997).

[0009] The generation of transgenic rabbits has been described by Fan, J. et al., Pathol Int 49: 583-94 (1999); Brem et al., *Mol Reprod Dev* 44: 56-62 (1996). Nuclear transfer cloning of rabbits has been described by Stice et al., *Biology of Reproduction* 39: 657-664 (1988). Rabbits with impaired immunoglobulin expression have been described by McCartney-Francis et al., *Mol Immunol* 24: 357-64 (1987); Allegrucci, et al., *Eur J Immunol* 21: 411-7 (1991).

[0010] The production of transgenic chicken has been described by Etches et al., *Methods in Molecular Biology* 62: 433-450; Pain et al., *Cells Tissues Organs* 1999; 165(3-4): 212-9; Sang, H., "Transgenic chickens—methods and potential applications", *Trends Biotechnol* 12:415 (1994); and in WO 200075300, "Introducing a nucleic acid into an avian genome, useful for transfecting avian blastodermal cells for producing transgenic avian animals with the desired genes, by directly introducing the nucleic acid into the germinal disc of the egg".

[0011] Agammaglobulinemic chicken have been described by Frommel et al., *J Immunol* 105(1): 1-6 (1970); Benedict et al., *Adv Exp Med Biol* 1977; 88(2): 197-205.

[0012] The cloning of animals from cells has been described by T. Wakayama et al., *Nature* 1998; 394:369-374; J. B. Cibelli et al., *Science* 280:1256-1258 (1998); J. B. Cibelli et al., *Nature Biotechnology* 1998; 16:642-646; A. E. Schnieke et al., *Science* 278: 2130-2133 (1997); K. H. Campbell et al., *Nature* 380: 64-66 (1996).

[0013] Production of antibodies from transgenic animals is described in U.S. Pat. Nos. 5,814,318, 5,545,807 and 5,570,429. Homologous recombination for chimeric mammalian hosts is exemplified in U.S. Pat. No. 5,416,260. A method for introducing DNA into an embryo is described in U.S. Pat. No. 5,567,607. Maintenance and expansion of embryonic stem cells is described in U.S. Pat. No. 5,453,357.

[0014] The mechanisms involved in the diversification of the antibody repertoire in pigs, sheep and cows are reviewed in Butler, J. E. (1998), "Immunoglobulin diversity, B-cell and antibody repertoire development in large farm animals", *Rev Sci Tech* 17:43. Antibody diversification in sheep is described in Reynaud, C. A., C. Garcia, W. R. Hein, and J. C. Weill (1995), "Hypermutation generating the sheep immunoglobulin repertoire is an antigen-independent process", *Cell* 80:115; and Dufour, V., S. Malinge, and F. Nau. (1996), "The sheep Ig variable region repertoire consists of a single VH family", *J Immunol* 156:2163.

SUMMARY OF THE INVENTION

[0015] One embodiment of the present invention provides humanized antibodies (humanized immunoglobulins) having at least a portion of a human immunoglobulin polypeptide sequence.

[0016] The humanized antibodies of the present invention are made from transgenic non-human animals genetically engineered to contain one or more humanized Ig loci.

[0017] Preferably, the humanized antibodies of the present invention are prepared from transgenic non-human animals which generate antibody diversity primarily by gene conversion and hypermutation, e.g., rabbit, pigs, chicken, sheep, cow and horse. The antibodies can be made by immunizing transgenic animals with a desired antigen such as an infectious agent (e.g., bacteria or viruses) or parts or fragments thereof.

[0018] Such humanized antibodies have reduced immunogenicity to primates, especially humans, as compared to non-humanized antibodies prepared from non-human animals. Therefore, the humanized antibodies of the present invention are appropriate for use in the therapeutic treatment of human subjects.

[0019] Another embodiment of the present invention provides a preparation of humanized antibodies which can be monoclonal antibodies or polyclonal antibodies. Preferred antibody preparations of the present invention are polyclonal antibody preparations which, according to the present invention, have minimal immunogenicity to primates, especially humans.

[0020] A preferred preparation of polyclonal antibodies is composed of humanized immunoglobulin molecules having at least a heavy chain or light chain constant region polypeptide sequence encoded by a human constant region gene segment. More preferably, the variable domains of the heavy chains or light chains of the immunoglobulins molecules are also encoded by human gene segments.

[0021] In another embodiment, the present invention provides pharmaceutical compositions which include a preparation of humanized antibodies, and a pharmaceutically-acceptable carrier.

[0022] Another embodiment of the present invention provides novel sequences from the 5' and 3' flanking regions of the Ig gene segments of non-human animals, preferably, animals which rely primarily on gene conversion in generating the antibody diversity. In particular, the present invention provides novel nucleotide sequences downstream (3', 3-prime) of the genes coding for Cλ in chickens, Cγ and Cϵ in rabbits, Cγ1,2,3 in cows and Cγ1,2 in sheep, as well as novel sequences 5' of rabbit Cγ.

[0023] In another embodiment, the present invention provides recombination vectors useful for replacing an Ig gene segment of a non-human animal with the corresponding human Ig gene segment. These vectors include a human Ig gene segment which is linked to flanking sequences at the 5' end and the 3' end, wherein the flanking sequences are homologous to the flanking sequences of the target animal Ig gene segment.

[0024] Preferred recombination vectors are those useful for the replacement of the animal's Ig constant region. For

example, recombination vectors useful for replacing the rabbit heavy chain constant region genes are provided. A preferred vector contains from 5' to 3', a nucleotide sequence as set forth in SEQ ID NO: 12 or SEQ ID NO: 13, or a portion of SEQ ID NO: 12 or SEQ ID NO: 13, a human heavy chain constant region gene segment, a nucleotide sequence as set forth in SEQ ID NO: 10 or a portion of or SEQ ID NO: 10. Another preferred vector contains a nucleotide sequence as set forth in SEQ ID NO: 51, which sequence is characterized as having a human Cγ1 gene linked to flanking sequences from the 5' and 3' flanking regions of a rabbit heavy chain constant region gene.

[0025] Recombination vectors are also provided useful for replacing the rabbit light chain constant region genes. A preferred vector contains a nucleotide sequence as set forth in SEQ ID NO: 53, which sequence is characterized as having a human Cκ linked to flanking sequences from the 5' and 3' flanking regions of the rabbit light chain Cγ1 gene.

[0026] Other recombination vectors are provided which are useful for replacing the chicken light chain constant region genes. A preferred vector contains a nucleotide sequence as set forth in SEQ ID NO: 57 which is characterized as having a human Cλ2 linked to flanking sequences from the 5' and 3' flanking regions of the chicken light chain Cλ gene.

[0027] Other recombination vectors provided include those useful for replacing the animal's Ig V region elements. For example, a recombination vector useful for replacing a rabbit heavy chain V region element is provided and contains SEQ ID NO: 52. A recombination vector usefull for replacing a rabbit light chain V region element is provided and contains SEQ ID NO: 54.

[0028] In still another embodiment, the present invention provides transgenic constructs or vectors containing at least one humanized Ig locus, i.e., an Ig locus from a non-human animal or a portion of an Ig locus from a non-human animal wherein the locus or the portion of a locus is genetically modified to contain at least one human Ig gene segment. Such humanized Ig locus has the capacity to undergo gene rearrangement and gene conversion in the non-human animal thereby producing a diversified repertoire of humanized immunoglobulins.

[0029] One humanized Ig locus provided by the invention is a humanized heavy chain locus which includes one or more V gene segments, one or more D gene segments, one or more J gene segments, and one or more constant region gene segments, wherein at least one gene segment is a human heavy chain gene segment. The gene segments in the humanized heavy chain locus are juxtaposed with respect to each other in an unrearranged, or partially or fully rearranged configuration. A preferred humanized heavy chain locus contains a human constant region gene segment, preferably,Cα or Cγ. A more preferred humanized locus contains multiple V gene segments and at least one human V gene segment, in addition to a human heavy chain constant region segment. The human V gene segment is placed downstream of the non-human V gene segments.

[0030] Another humanized Ig locus is a humanized light chain locus which includes one or more V gene segments, one or more J gene segments, and one or more constant region gene segments, wherein at least one gene segment is a human light chain gene segment. The gene segments in the humanized light chain locus are juxtaposed with respect to each other in an unrearranged or rearranged configuration. A preferred humanized light chain locus contains a human constant region gene segment, preferably, Cλ or Cκ. More preferably, the humanized light chain locus further contains multiple V gene segments and at least one human V gene segment. The human V gene segment is placed downstream of the non-human V gene segments. Even more preferably, the humanized light chain locus includes a rearranged human VJ segment, placed downstream of a number of (e.g., 10-100) VL gene segments of either non-human or human origin.

[0031] Another embodiment of the present invention is directed to methods of making a transgenic vector containing a humanized Ig locus by isolating an Ig locus or a portion of an Ig locus from a non-human animal, and integrating the desired human Ig gene segment(s) into the isolated animal Ig locus or the isolated portion of an Ig locus. The human Ig gene segment(s) are integrated into the isolated animal Ig locus or the isolated portion of an Ig locus by ligation or homologous recombination in such a way as to retain the capacity of the locus for undergoing effective gene rearrangement and gene conversion in the non-human animal. Integration of a human Ig gene segment by homologous recombination can be accomplished by using the recombination vectors of the present invention.

[0032] In another embodiment, the present invention provides methods of making transgenic animals capable of producing humanized antibodies. The transgenic animals can be made by introducing a transgenic vector containing a humanized Ig locus, or a recombination vector containing a human Ig gene segment, into a recipient cell or cells of an animal, and deriving an animal from the genetically modified recipient cell or cells.

[0033] Transgenic animals containing one or more humanized Ig loci, and cells derived from such transgenic animals (such as B cells from an immunized transgenic animal) are also provided. The transgenic animals of the present invention are capable of gene rearranging and gene converting the transgenic humanized Ig loci to produce a diversified repertoire of humanized immunoglobulin molecules.

BRIEF DESCRIPTION OF THE DRAWINGS

[0034] FIG. **1**. Cow Cγ 3' flanking sequences. Primers are shown in shaded boxes. The 5' primer is in CH3, and the 3' primer is in M1. The sequences of clone 11, clone 3, and clone 5 are set forth in SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5, respectively.

[0035] FIG. **2**. Sheep Cγ 3' flanking sequences. Primers are shown in shaded boxes. The 5' primer is in CH3, and the 3' primer is in M2. The sequences of clone 11 and clone 1 are set forth in SEQ ID NO: 8 and SEQ ID NO: 9, respectively.

[0036] FIG. **3**. A novel 3' flanking sequence (SEQ ID NO: 10) of the rabbit Cgamma gene.

[0037] FIG. **4**. A novel nucleotide sequence (SEQ ID NO: 11) 3' of the rabbit Ckappa 1 gene.

[0038] FIG. **5**. Novel nucleotide sequences (SEQ ID NO: 12 and SEQ ID NO: 13) 5' of the rabbit Cgamma gene. The

sequences between SEQ ID NO: 12 and SEQ ID NO: 13 (a gap of about 1000 nt) remain to be determined.

[0039] FIG. **6**. Comparison of human, mouse, rabbit, sheep, cow and camel sequences for the M1 and M2 regions 3' of the Cgamma gene.

[0040] FIG. **7***a*. DNA construct for the replacement of rabbit Cκ with human Cκ. A 0.5 kb fragment containing a DNA sequence encoding human Cλ is flanked by sequences from the rabbit Cκ1 gene. The upstream sequence (5'Cκ) is 2.8 kb, the downstream sequence (3'Cκ) is 2.6 kb. The vector also contains a lox-neo cassette for positive selection and a Hsv-Tk casette for negative selection.

[0041] FIG. **7***b*. DNA construct for the replacement of rabbit Cγ with human Cγ1. A 1.8 kb fragment containing a DNA sequence encoding human Cγ1 is flanked by sequences from the rabbit Cγ gene. The upstream sequence (5'Cγ) is 1.9 kb, the downstream sequence (3'Cγ) is 3.1 kb. The vector also contains a lox-neo casette for positive selection and a Hsv-Tk cassette for negative selection. The figure is not up to scale.

[0042] FIG. **8**. DNA fragment (SEQ ID NO: 51) containing a human immunoglobulin heavy chain Cγ1 gene segment flanked by 50 nucleotides derived from the flanking regions of rabbit Cγ gene. Flanking sequences derived from the flanking regions of rabbit Cγ gene are underlined.

[0043] FIG. **9**. DNA fragment (SEQ ID NO: 52) containing a V gene segment with more than 80% sequence identity with rabbit V elements and encoding a human V element polypeptide sequence. Flanking sequences derived from the flanking regions of rabbit VH1 and J genes are underlined.

[0044] FIG. **10**. DNA fragment (SEQ ID NO: 53) containing a human immunoglobulin heavy chain Cκ gene segment flanked by 50 nucleotides derived from the rabbit light chain immunoglobulin Kappal gene. Flanking sequences derived from the flanking regions of rabbit Cκ gene are underlined.

[0045] FIG. **11**. DNA fragment (SEQ ID NO: 54) containing a V gene segment with more than 80% sequence identity with rabbit V elements and encoding a human V element polypeptide sequence. Flanking sequences derived from the flanking regions of rabbit immunoglobulin V and J genes are underlined.

[0046] FIG. **12**. DNA fragment (SEQ ID NO: 57) containing a gene encoding human immunoglobulin light chain constant region Clambda2 flanked by 50 nucleotides (underlined) derived from the flanking sequences of chicken Clambda gene.

[0047] FIG. **13**. Modification of the chicken light chain locus using the ET system. A chicken genomic BAC clone with the full-length light chain locus was modified by homologous recombination. In a first step Cλ was deleted by insertion of a selection cassette which was in a second homologous recombination step exchanged against the human Cλ gene.

[0048] FIG. **14**. DNA fragment (SEQ ID NO: 58) containing a VJ gene segment with 80% sequence identity with chicken V gene segments and encoding a human VJ immunoglobulin polypeptide. Flanking sequences derived from the flanking regions of chicken immunolgobulin V and J genes are underlined.

[0049] FIG. **15**. Modified chicken light chain locus.

DETAILED DESCRIPTION OF THE INVENTION

[0050] One embodiment of the present invention provides humanized immunoglobulins (antibodies).

[0051] By "a humanized antibody" or "a humanized immunoglobulin" is meant an immunoglobulin molecule having at least a portion of a human immunoglobulin polypeptide sequence (or a polypeptide sequence encoded by a human Ig gene segment). The humanized immunoglobulin molecules of the present invention can be isolated from a transgenic non-human animal engineered to produce humanized immunoglobulin molecules. Such humanized immunoglobulin molecules are less immunogenic to primates, especially humans, relative to non-humanized immunoglobulin molecules prepared from the animal or prepared from cells derived from the animal.

[0052] The term "non-human animals" as used herein includes, but is not limited to, rabbits, pigs, birds (e.g., chickens, turkeys, ducks, geese and the like), sheep, goats, cows and horses. Preferred non-human animals are those animals which rely primarily on gene conversion and/or somatic hypermutation to generate antibody diversity, e.g., rabbit, pigs, birds (e.g., chicken, turkey, duck, goose and the like), sheep, goat, and cow. Particularly preferred non-human animals are rabbit and chicken.

[0053] In animals such as human and mouse, there are multiple copies of V, D and J gene segments on the heavy chain locus, and multiple copies of V and J gene segments on a light chain locus. Antibody diversity in these animals is generated primarily by gene rearrangement, i.e., different combinations of gene segments to form rearranged heavy chain variable region and light chain variable region. In other animals (e.g., rabbit, chicken, sheep, goat, and cow), however, gene rearrangement does not play a significant role in the generation of antibody diversity. For example, in rabbit, only a very limited number of the V gene segments, most often the V gene segments at the 3' end of the V-region, are used in gene rearrangement to form a contiguous VDJ segment. In chicken, only one V gene segment (the one adjacent to the D region, or "the 3' proximal V gene segment"), one D segment and one J segment are used in the heavy chain rearrangement; and only one V gene segment (the 3' proximal V segment) and one J segment are used in the light chain rearrangement. Thus, in these animals, there is little diversity among initially rearranged variable region sequences resulting from junctional diversification.

[0054] Further diversification of the rearranged Ig genes is achieved by gene conversion, a process in which short sequences derived from the upstream V gene segments replace short sequences within the V gene segment in the rearranged Ig gene.

[0055] The term "Ig gene segment" as used herein refers to segments of DNA encoding various portions of an Ig molecule, which are present in the germline of animals and humans, and which are brought together in B cells to form rearranged Ig genes. Thus, Ig gene segments as used herein include V gene segments, D gene segments, J gene segments and C region gene segments.

[0056] The term "human Ig gene segment" as used herein includes both naturally occurring sequences of a human Ig gene segment, degenerate forms of naturally occurring

sequences of a human Ig gene segment, as well as synthetic sequences that encode a polypeptide sequence substantially identical to the polypeptide encoded by a naturally occurring sequence of a human Ig gene segment. By "substantially" is meant that the degree of amino acid sequence identity is at least about 85%-95%.

[0057] A preferred humanized immunoglobulin molecule of the present invention contains at least a portion of a human heavy or light chain constant region polypeptide sequence. A more preferred immunoglobulin molecule contains at least a portion of a human heavy or light chain constant region polypeptide sequence, and at least a portion of a human variable domain polypeptide sequence.

[0058] In another embodiment of the present invention, a preparation of humanized antibodies is provided.

[0059] By "a preparation of humanized antibodies" or "a humanized antibody preparation" is meant an isolated antibody product or a purified antibody product prepared from a transgenic non-human animal (e.g., serum, milk, or egg yolk of the animal) or from cells derived from a transgenic non-human animal (e.g., a B-cell or a hybridoma cell).

[0060] A humanized antibody preparation can be a preparation of polyclonal antibodies, which includes a repertoire of humanized immunoglobulin molecules. A humanized antibody preparation can also be a preparation of a monoclonal antibody.

[0061] Although the immunogenicity to humans of a humanized monoclonal antibody preparation is also reduced as compared to a non-humanized monoclonal antibody preparation, humanized polyclonal antibody preparations are preferred embodiments of the present invention. It has been recognized that humanized monoclonal antibodies still invoke some degree of an immune response (an anti-idiotype response) in primates (e.g., humans) when administered repeatedly in large quantities because of the unique and novel idiotype of the monoclonal antibody. The present inventors have uniquely recognized that the overall immunogenicity of polyclonal antibodies is less dependent on an anti-idiotype response. For example, polyclonal antibodies made from non-human animals with only the constant region elements humanized (e.g., polyclonal antibodies having constant regions encoded by human gene segments, and having variable domains encoded by the endogenous genes of the non-human animal), are substantially non-immunogenic to primates.

[0062] Without intending to be bound to any theory, the present inventors have proposed that the reduced immunogenicity of such a humanized polyclonal antibody preparation is due to the fact that the preparation contains a very large number of different antibodies with many different idiotypes which are to a large extent defined by novel amino acid sequences in the complimentarity determining regions (CDR) of the heavy and light chain. Therefore, upon administration of such preparation into a primate such as a human, the administered amount of each individual immunoglobulin molecule in the preparation may be too low to solicit immune response against each immunoglobulin molecule. Thus, the humanized polyclonal antibody preparation which has many different idiotypes and variable regions has minimal immunogenicity to a recipient, even if the antibodies in the polyclonal antibody preparation are all directed to the same antigen. To further reduce any potential residual immunogenicity, a humanized polyclonal antibody preparation may be prepared which is composed of immunoglobulin molecules having both the variable domains and the constant regions encoded by human Ig gene segments.

[0063] In a preferred embodiment, the present invention provides an antibody preparation which includes humanized immunoglobulin molecules having at least a portion of a human heavy or light chain constant region polypeptide sequence. More preferably, the humanized immunoglobulines in the antibody preparation of the present invention further contain at least a portion of a human variable domain polypeptide sequence, in addition to at least a portion of a human constant region polypeptide sequence.

[0064] Preferred humanized antibody preparations of the present invention are composed of humanized antibodies made from transgenic non-human animals whose antibody diversity is generated primarily by gene conversion, such as rabbit, birds (e.g., chicken, turkey, duck, goose and the like), sheep, goat, and cow; preferably, rabbit and chicken.

[0065] Once a transgenic non-human animal capable of producing diversified humanized immunoglobulin molecules is made (as further set forth below), humanized immunoglobulins and humanized antibody preparations against an antigen can be readily obtained by immunizing the animal with the antigen. A variety of antigens can be used to immunize a transgenic host animal. Such antigens include, microorganism, e.g. viruses and unicellular organisms (such as bacteria and fungi), alive, attenuated or dead, fragments of the microorganisms, or antigenic molecules isolated from the microorganisms.

[0066] Preferred bacterial antigens for use in immunizing an animal include purified antigens from *Staphylococcus aureus* such as capsular polysaccharides type 5 and 8, recombinant versions of virulence factors such as alpha-toxin, adhesin binding proteins, collagen binding proteins, and fibronectin binding proteins. Preferred bacterial antigens also include an attenuated version of *S. aureus, Pseudomonas aeruginosa, enterococcus, enterobacter*, and *Klebsiella pneumoniae*, or culture supernatant from these bacteria cells. Other bacterial antigens which can be used in immunization include purified lipopolysaccharide (LPS), capsular antigens, capsular polysaccharides and/or recombinant versions of the outer membrane proteins, fibronectin binding proteins, endotoxin, and exotoxin from *Pseudomonas aeruginosa, enterococcus, enterobacter*, and *Klebsiella pneumomae.*

[0067] Preferred antigens for the generation of antibodies against fungi include attenuated version of fungi or outer membrane proteins thereof, which fungi include, but are not limited to, *Candida albicans, Candida parapsilosis, Candida tropicalis*, and *Cryptococcus neoformans.*

[0068] Preferred antigens for use in immunization in order to generate antibodies against viruses include the envelop proteins and attenuated versions of viruses which include, but are not limited to respiratory synctial virus (RSV) (particularly the F-Protein), Hepatitis C virus (HCV), Hepatits B virus (HBV), cytomegalovirus (CMV), EBV, and HSV.

[0069] Therapeutic antibodies can be generated for the treatment of cancer by immunizing transgenic animals with

isolated tumor cells or tumor cell lines; tumor-associated antigens which include, but are not limited to, Her-2-neu antigen (antibodies against which are useful for the treatment of breast cancer); CD20, CD22 and CD53 antigens (antibodies against which are useful for the treatment of B cell lymphomas), (3) prostate specific membrane antigen (PMSA) (antibodies against which are useful for the treatment of prostate cancer), and 17-1A molecule (antibodies against which are useful for the treatment of colon cancer).

[0070] The antigens can be administered to a transgenic host animal in any convenient manner, with or without an adjuvant, and can be administered in accordance with a predetermined schedule.

[0071] After immunization, serum or milk from the immunized transgenic animals can be fractionated for the purification of pharmaceutical grade polyclonal antibodies specific for the antigen. In the case of transgenic birds, antibodies can also be made by fractionating egg yolks. A concentrated, purified immunoglobulin fraction may be obtained by chromatography (affinity, ionic exchange, gel filtration, etc.), selective precipitation with salts such as ammonium sulfate, organic solvents such as ethanol, or polymers such as polyethyleneglycol.

[0072] For making a monoclonal antibody, spleen cells are isolated from the immunized transgenic animal and used either in cell fusion with transformed cell lines for the production of hybridomas, or cDNAs encoding antibodies are cloned by standard molecular-biology techniques and expressed in transfected cells. The procedures for making monoclonal antibodies are well established in the art. See, e.g., European Patent Application 0 583 980 A1 ("Method For Generating Monoclonal Antibodies From Rabbits"), U.S. Pat. No. 4,977,081 ("Stable Rabbit-Mouse Hybridomas And Secretion Products Thereof"), WO 97/16537 ("Stable Chicken B-cell Line And Method of Use Thereof"), and EP 0 491 057 B1 ("Hybridoma Which Produces Avian Specific Immunoglobulin G"), the disclosures of which are incorporated herein by reference. In vitro production of monoclonal antibodies from cloned cDNA molecules has been described by Andris-Widhopf et al., "Methods for the generation of chicken monoclonal antibody fragments by phage display", *J Immunol Methods* 242:159 (2000), and by Burton, D. R, "Phage display", *Immunotechnology* 1:87 (1995), the disclosures of which are incorporated herein by reference.

[0073] In a further embodiment of the present invention, purified monoclonal or polyclonal antibodies are admixed with an appropriate pharmaceutical carrier suitable for administration in primates especially humans, to provide pharmaceutical compositions.

[0074] Pharmaceutically acceptable carriers which can be employed in the present pharmaceutical compositions can be any and all solvents, dispersion media, isotonic agents and the like. Except insofar as any conventional media, agent, diluent or carrier is detrimental to the recipient or to the therapeutic effectiveness of the antibodies contained therein, its use in the pharmaceutical compositions of the present invention is appropriate. The carrier can be liquid, semi-solid, e.g. pastes, or solid carriers. Examples of carriers include oils, water, saline solutions, alcohol, sugar, gel, lipids, liposomes, resins, porous matrices, binders, fillers, coatings, preservatives and the like, or combinations thereof

[0075] The present invention is further directed to novel nucleotide sequences and vectors, as well as the use of the sequences and vectors in making a transgenic non-human animal which produces humanized immunoglobulins.

[0076] In general, the genetic engineering of a non-human animal involves the integration of one or more human Ig gene segments into the animal's genome to create one or more humanized Ig loci. It should be recognized that, depending upon the approach used in the genetic modification, a human Ig gene segment can be integrated at the endogenous Ig locus of the animal (as a result of targeted insertion, for example), or at a different locus of the animal. In other words, a humanized Ig locus can reside at the chromosomal location where the endogenous Ig locus of the animal ordinarily resides, or at a chromosomal location other than where the endogenous Ig locus of the animal ordinarily resides. Regardless of the chromosomal location, a humanized Ig locus of the present invention has the capacity to undergo gene rearrangement and gene conversion in the non-human animal thereby producing a diversified repertoire of humanized immunoglobulin molecules. An Ig locus having the capacity to undergo gene rearrangement and gene conversion is also referred to herein as a "functional" Ig locus, and the antibodies with a diversity generated by a functional Ig locus are also referred to herein as "functional" antibodies or a "functional" repertoire of antibodies.

[0077] In one embodiment, the present invention provides novel sequences useful for creating a humanized Ig locus and making transgenic animals capable of producing humanized immunoglobulin molecules. In particular, the present invention provides sequences from the 5' and 3' flanking regions of the Ig gene segments of non-human animals, preferably, animals which rely primarily on gene conversion in generating antibody diversity (e.g., rabbit, pigs, sheep, goat, cow, birds such as chicken, turkey, duck, goose, and the like).

[0078] The 5' and 3' flanking regions of the genes coding for the constant region are particularly important as these sequences contain untranslated regulatory elements (e.g., enhancers) critical for high Ig expression in the serum. The 3' flanking region of the genes coding for the constant region of the heavy chain also contain exons coding for the membranous and cytoplasmic tail of the membrane form of immunoglobulin (Volgina et al. *J Immunol* 165:6400, 2000). It has been previously established that the membrane and cytoplasmic tail of the membrane form of antibodies are critical in achieving a high level of expression of the antibodies in mice sera (Zou et al., *Science* 262:1271, 1993). Thus, the identification of the flanking sequences permits the replacement of exons and intervening introns of the Cγ gene with the human equivalent, and the maintenance of the endogenous exons encoding the transmembrane and cytoplasmic tail regions as well as the endogenous non-coding enhancer sequences.

[0079] In one embodiment, the present invention provides 3' flanking sequences of heavy chain constant regions of non-human animals. More particularly, nucleotide sequences downstream (3', 3-prime) of the genes coding for rabbit Cγ, cow Cγ1,2,3, and sheep Cγ1,2 are provided. Especially preferred nucleotide sequences include SEQ ID NO: 10 (3' of rabbit Cγ), SEQ ID NOS: 3-5 (3' of cow Cγ1,2,3), and SEQ ID NOS: 8-9 (3' of sheep Cγ1,2).

[0080] In another embodiment, the present invention provides 3' flanking sequences of light chain constant regions of

non-human animals. More particularly, the present invention provides nucleotide sequences downstream (3', 3-prime) of the genes coding for Cκ in rabbits. Especially preferred nucleotide sequences include SEQ ID NO: 11 (3' of rabbit Cκ).

[0081] In still another embodiment, the present invention provides 5' flanking sequences of heavy chain constant regions of non-human animals. More particularly, nucleotide sequences upstream (5', 5-prime) of the rabbit Cγ gene are provided. Especially preferred sequences include SEQ ID NO: 12 and SEQ ID NO: 13.

[0082] Another embodiment of the present invention provides 5' flanking sequences of light chain constant regions of non-human animals.

[0083] Portions of the above novel flanking sequences are provided by the present invention. By "a portion" is meant a fragment of a flanking nucleotide sequence capable of mediating homologous recombination between the human Ig gene segment and the target animal Ig gene segment. Generally, a portion is at least about 200 base pairs, preferably, at least about 400 base pairs, for recombination in animal cells such as ES cells or fibroblasts, and at least about 40 base pairs, preferably at least about 50 base pairs, for recombination in *E. coli*. Examples of portions of the above novel flanking-sequences include SEQ ID NOS: 59-60, 61-62, 63-64, 65-66, 67-68 and 69-70 (represented by the underlined sequences in FIGS. **8-12** and **14**, respectively).

[0084] In a further aspect, the present invention provides vectors useful for the replacement of an Ig gene segment of a non-human animal with the corresponding human Ig gene segment. These vectors, also referred to herein as "recombination vectors", include a human Ig gene segment which is linked to flanking sequences at the 5' end and the 3' end, wherein the flanking sequences have a degree of homology with the flanking sequences of the target animal Ig gene segment sufficient to mediate homologous recombination between the human gene and the animal gene segments. Generally, at least about 200 bases should be identical between the flanking regions in a recombination vector and the flanking regions of the target gene to achieve efficient homologous recombination in animal cells such as ES cells and fibroblasts; and at least about 40 bases should be identical to achieve efficient homologous recombination in *E. coli*.

[0085] Recombination vectors useful for replacing the animal's immunoglobulin heavy chain constant region genes are provided, which contain from 5' to 3', a nucleotide sequence homologous to the 5' flanking region of the target animal heavy chain constant region gene, a human heavy chain constant region gene (e.g., human Cγ1), and a nucleotide sequence homologous to the 3' flanking region of the target animal heavy chain constant region gene.

[0086] Preferred recombination vectors are provided for the replacement of the rabbit heavy chain constant region genes. One such vector contains from 5' to 3', a nucleotide sequence as set forth in SEQ ID NO: 12 or SEQ ID NO: 13 or a portion thereof, a human heavy chain constant region gene segment, a nucleotide sequence as set forth in SEQ ID NO: 10 or a portion of or SEQ ID NO: 10. Another such vector contains SEQ ID NO: 51 (FIG. **8**) which is characterized as having a human Cγ1 gene linked to flanking sequences from the 5' and 3' flanking regions of a rabbit heavy chain constant region gene.

[0087] Recombination vectors are also provided which are useful for replacing the animal's immunoglobulin light chain constant region genes. Such vectors contain from 5' to 3', a nucleotide sequence homologous to the 5' flanking region of the target light chain constant region gene, a human light chain constant region gene (e.g., human Cκ or Cλ)), and a nucleotide sequence homologous to the 3' flanking region of the target light chain constant region gene.

[0088] Preferred vectors include those useful for replacing the rabbit light chain constant region genes. A preferred vector contains a nucleotide sequence as set forth in SEQ ID NO: 53, which sequence is characterized as having a human Cκ linked to flanking sequences from the 5' and 3' flanking regions of the rabbit light chain Cκ1 gene.

[0089] Other recombination vectors provided include those useful for replacing the animal's Ig V region elements. For example, a recombination vector useful for replacing a rabbit heavy chain V region element is provided and contains SEQ ID NO: 52. A recombination vector useful for replacing a rabbit light chain V region element is provided and contains SEQ ID NO: 54.

[0090] The recombination vectors of the present invention can include additional sequences that facilitate the selection of cells which have undergone a successful recombination event. For example, marker genes coding for resistance to neomycin, bleomycin, puromycin and the like can be included in the recombination vectors to facilitate the selection of cells which have undergone a successful recombination event.

[0091] In a further aspect of the present invention, transgenic constructs or vectors carrying one or more humanized Ig loci are provided.

[0092] In one embodiment, the present invention provides transgenic constructs containing a humanized Ig heavy chain locus which includes one or more V gene segments, one or more D gene segments, one or more J gene segments, and one or more constant region gene segments, wherein at least one gene segment is a human heavy chain gene segment. The gene segments in such humanized heavy chain locus are juxtaposed wit respect to each other in an unrearranged configuration (or "the germline configuration"), or in a partially or fully rearranged configuration. The humanized heavy chain locus has the capacity to undergo gene rearrangement (if the gene segments are not fully rearranged) and gene conversion in the non-human animal thereby producing a diversified repertoire of heavy chains having human polypeptide sequences, or "humanized heavy chains".

[0093] In a preferred embodiment, the humanized heavy chain locus contains at least one C-region gene segment that is a human constant region gene segment, preferably, Cα or Cγ (including any of the Cγ subclasses 1, 2, 3 and 4).

[0094] In another more preferred embodiment, the humanized heavy chain locus of the transgene contains a humanized V-region and a humanized C-region, i.e., a V-region having at least one human VH gene segment and a C-region having at least one human C gene segment (e.g., human Cα or Cγ).

[0095] Preferably, the humanized V-region includes at least about 10-100 heavy chain V (or "VH") gene segments, at least one of which is a human VH gene segment. In accordance with the present invention, the human VH gene segment included in the transgene shares at least about 75% to about 85% homology to the VH gene segments of the host animal, particularly those animal VH gene segments included in the upstream region of the transgene. As described above, a human VH segment encompasses naturally occurring sequences of a human VH gene segment, degenerate forms of naturally occurring sequences of a human VH gene segment, as well as synthetic sequences that encode a polypeptide sequence substantially (i.e., at least about 85%-95%) identical to a human heavy chain V domain polypeptide.

[0096] Preferably, the human VH gene segment(s) is placed downstream of the non-human VH segments in the transgene locus. Preferably, the non-human VH gene segments in the transgene are the VH gene segments from the 3' VH-region in the Ig locus of the host animal, including the 3' proximal VH1.

[0097] In another embodiment, the present invention provides transgenic constructs containing a humanized light chain locus capable of undergoing gene rearrangement and gene conversion in the host animal thereby producing a diversified repertoire of light chains having human polypeptide sequences, or "humanized light chains".

[0098] The humanized light locus includes one or more V gene segments, one or more J gene segments, and one or more constant region gene segments, wherein at least one gene segment is a human light chain gene segment. The gene segments in the humanized light chain locus are juxtaposed in an unrearranged configuration (or "the germline configuration"), or fully rearranged configuration.

[0099] In a preferred embodiment, the humanized light chain locus contains at least one C-region gene segment that is a human constant region gene segment, preferably, Cλ or Cκ.

[0100] In another preferred embodiment, the humanized light chain locus of the transgene contains a humanized V-region and a humanized C-region, e.g., a V-region having at least one human VL gene and/or at least one rearranged human VJ segment, and a C-region having at least one human C gene segment (e.g., human Cλ or Cκ).

[0101] Preferably, the humanized V-region includes at least about 10-100 light chain V (or "VL") gene segments, at least one of which is a human VL gene segment. The human VL gene segment included in the transgene shares at least about 75% to about 85% homology to the VL gene segments of the host animal, particularly those animal VL gene segments included in the upstream region of the transgene. Consistently, a human VL segment encompasses naturally occurring sequences of a human VL gene segment, degenerate forms of naturally occurring sequences of a human VL gene segment, as well as synthetic sequences that encode a polypeptide sequence substantially (i.e., at least about 85%-95%) identical to a human light chain V domain polypeptide.

[0102] Preferably, the human VL gene segment(s) is placed downstream of the non-human VL segments in the transgene locus. The non-human VL gene segments in the transgene construct are selected from the VL gene segments in the 3'VL-region in the light chain locus of the host animal, including the 3' proximal VL1.

[0103] In still another preferred embodiment, the humanized light chain locus includes a rearranged human VJ segment, placed downstream of a number of (e.g., 10-100) VL gene segments of either non-human or human origin.

[0104] Another aspect of the present invention is directed to methods of making a transgenic vector containing a humanized Ig locus. Such methods involve isolating an Ig locus or a portion thereof from a non-human animal, and inserting the desired human Ig gene segment(s) into the isolated animal Ig locus or the isolated portion of an animal Ig locus. The human Ig gene segment(s) are inserted into the isolated animal Ig locus or a portion thereof by ligation or homologous recombination in such a way as to retain the capacity of the locus of undergoing effective gene rearrangement and gene conversion in the non-human animal.

[0105] Preferably, DNA fragments containing an Ig locus to be humanized are isolated from animals which generate antibody diversity by gene conversion, e.g., rabbit and chicken. Such large DNA fragments can be isolated by screening a library of plasmids, cosmids, YACs or BACs, and the like, prepared from the genomic DNA of the non-human animal. An entire animal C-region can be contained in one plasmid or cosmid clone which is subsequently subjected to humanization. YAC clones can carry DNA fragments of up to 2 megabases, thus an entire animal heavy chain locus or a large portion thereof can be isolated in one YAC clone, or reconstructed to be contained in one YAC clone. BAC clones are capable of carrying DNA fragments of smaller sizes (about 150-250 kb). However, multiple BAC clones containing overlapping fragments of an Ig locus can be separately humanized and subsequently injected together into an animal recipient cell, wherein the overlapping fragments recombine in the recipient animal cell to generate a continuous Ig locus.

[0106] Human Ig gene segments can be integrated into the Ig locus on a vector (e.g., a BAC clone) by a variety of methods, including ligation of DNA fragments, or insertion of DNA fragments by homologous recombination. Integration of the human Ig gene segments is done in such a way that the human Ig gene segment is operably linked to the host animal sequence in the transgene to produce a functional humanized Ig locus, i.e., an Ig locus capable of gene rearrangement and gene conversion which lead to the production of a diversified repertoire of humanized antibodies.

[0107] Preferably, human Ig gene segments are integrated into the Ig locus by homologous recombination. Homologous recombination can be performed in bacteria, yeast and other cells with a high frequency of homologous recombination events. For example, a yeast cell is transformed with a YAC containing an animal's Ig locus or a large portion thereof. Subsequently, such yeast cell is further transformed with a recombination vector as described hereinabove, which carries a human Ig gene segment linked to a 5' flanking sequence and a 3' flanking sequence. The 5' and the 3' flanking sequences in the recombination vector are homologous to those flanking sequences of the animal Ig gene segment on the YAC. As a result of a homologous' recombination, the animal Ig gene segment on the YAC is replaced with the human Ig gene segment. Alternatively, a

bacterial cell such as *E. coli* is transformed with a BAC containing an animal's Ig locus or a large portion thereof. Such bacterial cell is further transformed with a recombination vector which carries a human Ig gene segment linked to a 5' flanking sequence and a 3' flanking sequence. The 5' and the 3' flanking sequences in the recombination vector mediate homologous recombination and exchange between the human Ig gene segment on the recombination vector and the animal Ig gene segment on the BAC. Humanized YACs and BACs can be readily isolated from the cells and used in making transgenic animals.

[0108] In a further aspect of the present invention, methods of making transgenic animals capable of producing humanized immunoglobulins are provided.

[0109] According to the present invention, a transgenic animal capable of making humanized immunoglobulins are made by introducing into a recipient cell or cells of an animal one or more of the transgenic vectors described herein above which carry a humanized Ig locus, and deriving an animal from the genetically modified recipient cell or cells.

[0110] Preferably, the recipient cells are from non-human animals which generate antibody diversity by gene conversion and hypermutation, e.g., bird (such as chicken), rabbit, cows and the like. In such animals, the 3'proximal V gene segment is preferentially used for the production of immunoglobulins. Integration of a human V gene segment into the Ig locus on the transgene vector, either by replacing the 3'proximal V gene segment of the animal or by being placed in close proximity of the 3'proximal V gene segment, results in expression of human V region polypeptide sequences in the majority of immunoglobulins. Alternatively, a rearranged human V(D)J segment may be inserted into the J locus of the immunoglobulin locus on the transgene vector.

[0111] The transgenic vectors containing a humanized Ig locus is introduced into the recipient cell or cells and then integrated into the genome of the recipient cell or cells by random integration or by targeted integration.

[0112] For random integration, a transgenic vector containing a humanized Ig locus can be introduced into an animal recipient cell by standard transgenic technology. For example, a transgenic vector can be directly injected into the pronucleus of a fertilized oocyte. A transgenic vector can also be introduced by co-incubation of sperm with the transgenic vector before fertilization of the oocyte. Transgenic animals can be developed from fertilized oocytes. Another way to introduce a transgenic vector is by transfecting embryonic stem cells and subsequently injecting the genetically modified embryonic stem cells into developing embryos. Alternatively, a transgenic vector (naked or in combination with facilitating reagents) can be directly injected into a developing embryo. Ultimately, chimeric transgenic animals are produced from the embryos which contain the humanized Ig transgene integrated in the genome of at least some somatic cells of the transgenic animal.

[0113] In a preferred embodiment, a transgene containing a humanized Ig locus is randomly integrated into the genome of recipient cells (such as fertilized oocyte or developing embryos) derived from animal stras with an impaired expression of endogenous immunoglobulin genes. The use of such animal strains permits preferential expression of immunoglobulin molecules from the humanized transgenic Ig locus. Examples for such animals include the Alicia and Basilea rabbit strains, as well as Agammaglobinemic chicken strain. Alternatively, transgenic animals with humanized immunoglobulin transgenes or loci can be mated with animal strains with impaired expression of endogenous immunoglobulins. Offspring homozygous for an impaired endogenous Ig locus and a humanized transgenic Ig locus can be obtained.

[0114] For targeted integration, a transgenic vector can be introduced into appropriate animal recipient cells such as embryonic stem cells or already differentiated somatic cells. Afterwards, cells in which the transgene has integrated into the animal genome and has replaced the corresponding endogenous Ig locus by homologous recombination can be selected by standard methods. The selected cells may then be fused with enucleated nuclear transfer unit cells, e.g. oocytes or embryonic stem cells, cells which are totipotent and capable of forming a functional neonate. Fusion is performed in accordance with conventional techniques which are well established. See, for example, Cibelli et al., Science (1998) 280:1256. Enucleation of oocytes and nuclear transfer can also be performed by microsurgery using injection pipettes. (See, for example, Wakayama et al., Nature (1998) 394:369.) The resulting egg cells are then cultivated in an appropriate medium, and transferred into synchronized recipients for generating transgenic animals. Alternatively, the selected genetically modified cells can be injected into developing embryos which are subsequently developed into chimeric animals.

[0115] Further to the present invention, a transgenic animal capable of producing humanized immunoglobulins can also be made by introducing into a recipient cell or cells, one or more of the recombination vectors described herein above, which carry a human Ig gene segment, linked to 5' and 3' flanking sequences that are homologous to the flanking sequences of the endogenous Ig gene segment, selecting cells in which the endogenous Ig gene segment is replaced by the human Ig gene segment by homologous recombination, and deriving an animal from the selected genetically modified recipient cell or cells.

[0116] Similar to the target insertion of a transgenic vector, cells appropriate for use as recipient cells in this approach include embryonic stem cells or already differentiated somatic cells. A recombination vector carrying a human Ig gene segment can be introduced into such recipient cells by any feasible means, e.g., transfection. Afterwards, cells in which the human Ig gene segment has replaced the corresponding endogenous Ig gene segment by homologous recombination, can be selected by standard methods. These genetically modified cells can serve as nuclei donor cells in a nuclear transfer procedure for cloning a transgenic animal. Alternatively, the selected genetically modified embryonic stem cells can be injected into developing embryos which can be subsequently developed into chimeric animals.

[0117] Transgenic animals produced by any of the foregoing methods form another embodiment of the present invention. The transgenic animals have at least one, i.e., one or more, humanized Ig loci in the genome, from which a functional repertoire of humanized antibodies is produced.

[0118] In a preferred embodiment, the present invention provides transgenic rabbits having one or more humanized

Ig loci in the genome. The transgenic rabbits of the present invention are capable of rearranging and gene converting the humanized Ig loci, and expressing a functional repertoire of humanized antibodies.

[0119] In another preferred embodiment, the present invention provides transgenic chickens having one or more humanized Ig loci in the genome. The transgenic chickens of the present invention are capable of rearranging and gene converting the humanized Ig loci, and expressing a functional repertoire of humanized antibodies.

[0120] Cells derived from the transgenic animals of the present invention, such as B cells or cell lines established from a transgenic animal immunized against an antigen, are also part of the present invention.

[0121] In a further aspect of the present invention, methods are provided for treating a disease in a primate, in particular, a human subject, by administering a purified humanized antibody composition, preferably, a humanized polyclonal antibody composition, desirable for treating such disease.

[0122] The humanized polyclonal antibody compositions used for administration are generally characterized by containing a polyclonal antibody population, having immunoglobulin concentrations from 0.1 to 100 mg/ml, more usually from 1 to 10 mg/ml. The antibody composition may contain immunoglobulins of various isotypes. Alternatively, the antibody composition may contain antibodies of only one isotype, or a number of selected isotypes.

[0123] In most instances the antibody composition consists of unmodified immunoglobulins, i.e., humanized antibodies prepared from the animal without additional modification, e.g., by chemicals or enzymes. Alternatively, the immunoglobulin fraction may be subject to treatment such as enzymatic digestion (e.g. with pepsin, papain, plasmin, glycosidases, nucleases, etc.), heating, etc, and/or further fractionated.

[0124] The antibody compositions generally are administered into the vascular system, conveniently intravenously by injection or infusion via a catheter implanted into an appropriate vein. The antibody composition is administered at an appropriate rate, generally ranging from about 10 minutes to about 24 hours, more commonly from about 30 minutes to about 6 hours, in accordance with the rate at which the liquid can be accepted by the patient. Administration of the effective dosage may occur in a single infusion or in a series of infusions. Repeated infusions may be administered once a day, once a week once a month, or once every three months, depending on the half-life of the antibody preparation and the clinical indication. For applications on epithelial surfaces the antibody compositions are applied to the surface in need of treatment in an amount sufficient to provide the intended end result, and can be repeated as needed.

[0125] The antibody compositions can be used to bind and neutralize antigenic entities in human body tissues that cause disease or that elicit undesired or abnormal immune responses. An "antigenic entity" is herein defined to encompass any soluble or cell-surface bound molecules including proteins, as well as cells or infectious disease-causing organisms or agents that are at least capable of binding to an antibody and preferably are also capable of stimulating an immune response.

[0126] Administration of an antibody composition against an infectious agent as a monotherapy or in combination with chemotherapy results in elimination of infectious particles. A single administration of antibodies decreases the number of infectious particles generally 10 to 100 fold, more commonly more than 1000-fold. Similarly, antibody therapy in patients with a malignant disease employed as a monotherapy or in combination with chemotherapy reduces the number of malignant cells generally 10 to 100 fold, or more than 1000-fold. Therapy may be repeated over an extended amount of time to assure the complete elimination of infectious particles, malignant cells, etc. In some instances, therapy with antibody preparations will be continued for extended periods of time in the absence of detectable amounts of infectious particles or undesirable cells. Similarly, the use of antibody therapy for the modulation of immune responses may consist of single or multiple administrations of therapeutic antibodies. Therapy may be continued for extended periods of time in the absence of any disease symptoms.

[0127] The subject treatment may be employed in conjunction with chemotherapy at dosages sufficient to inhibit infectious disease or malignancies. In autoimmune disease patients or transplant recipients, antibody therapy may be employed in conjunction with immunosuppressive therapy at dosages sufficient to inhibit immune reactions.

[0128] The invention is further illustrated, but by no means limited, by the following examples.

EXAMPLE 1

Novel Sequences 3'Prime of the Cγ Gene from Cows, Sheep and Rabbits

[0129] Genomic DNA was isolated from blood of a Simmental cow using the QIAamp DNA Blood Kit (QIAGEN). The genomic region 3' of the cow Cγ gene (i.e., the cow Cγ gene 3' flanking sequence) was PCR-amplifled using the isolated genomic DNA as template and the following primers:

```
5' primer:
5'cgcaagcttCCTACACGTGTGTGGTGATG3';   (SEQ ID NO: 1)

3' primer:
5'cgcaagcttAAGATGGWGATGGTSGTCCA3'    (SEQ ID NO: 2)
```

The upper-case portion of the 5' primer was from exon 3 of Cγ, and the lower-case portion represented a terminal HindIII restriction site. The upper-case portion of the 3' primer was a degenerate sequence designed according to the published sequences from the human M1 exon and the mouse M1 exon, and the lower-case portion represented a terminal HindIII restriction site. A 1.3 kb PCR fragment was obtained using the EXPAND long template PCR system (Roche). The fragment was gel purified, digested with HindIII, and cloned into a Bluescript cloning vector. The resulting clones fell into three populations, which differ from one another in the pattern of the restriction fragments obtained with BamHI, EcoRI and XhoI. One clone from each population was sequenced, and the sequences are shown in FIG. **1** (SEQ ID NOS: 3-5).

[0130] Genomic DNA was isolated from blood of a Merino sheep using the QIAamp DNA Blood Kit

(QIAGEN). The genomic region 3' of the sheep Cγ gene (i.e., the sheep Cγ gene 3' flanking sequence) was PCR-amplified using the isolated genomic DNA as template and the following primers:

```
5' primer:
5'cgcggatccCCTACGCGTGTGTGGTGATG3'    (SEQ ID NO: 6)

3' primer:
5'cgcggatccACCGAGGAGAAGATCCACTT3'    (SEQ ID NO: 7)
```

The upper-case portion of the 5' primer was from exon 3 of Cγ, and the lower-case portion represented a terminal BamHI restriction site. The upper-case portion of the 3' primer was designed according to the published sequences from the human M2 exon and the mouse M2 exon, and the lower-case portion represented a terminal BamHI restriction site. A 2.9 kb PCR fragment was obtained using the EXPAND long template PCR system (Roche). The fragment was gel purified, digested with BamHII, and cloned into a Bluescript cloning vector. The resulting clones fell into two populations, which differ from each other in the pattern of the restriction fragments obtained with HindIII, EcoRI and XhoI. One clone from each population was sequenced, and the sequences are shown in FIG. **2** (SEQ ID NOS: 8-9).

[0131] A 10 kb EcoRI fragment containing the Cγ gene and its flanking sequences from A2 allotype rabbit was subcloned from a genomic cosmid clone (cos 8.3 from Knight et al., *J Immunol (*1985) 1245-50, "Organization and polymorphism of rabbit immunoglobulin heavy chain genes"). The nucleotide sequences 5' and 3' of Cγ were determined using standard methods and are set forth in FIG. **3** and 5, SEQ ID NO: 10, 12, 13, respectively.

[0132] Sequences 3' of rabbit Ckappal were determined from an EcoRI/BamHI subclone from VJk2CλIn pSV2neo. The nucleotide sequence is set forth in FIG. **4**, SEQ ID NO: 11.

[0133] The amino acid sequences encoded by the M1 and M2 exons from cow, sheep and rabbit were deduced from the above 3' flanking sequence. These amino acid sequences were aligned with the published M1 and M2 sequences from camel, human and mouse, as shown in FIG. **6**.

EXAMPLE 2

A Vector for Replacing the Rabbit Endogenous Cγ Gene Segment with the Human Cγ1 Segment

[0134] Genomic DNA is isolated from rabbit fetal fibroblasts of an a2-homozygous rabbit. The DNA sequence upstream of rabbit Cγ (i.e., the 5' flanking sequence of rabbit Cγ) is amplified by PCR using the following primers:

```
5' taattatgcggccgcCTTCAGCGTGAACCAC (SEQ ID NO: 39)
GCCCTC 3'
with a 5' NotI site and

5' GTCGACGCCCCTCGATGCACTCCCAGAG    (SEQ ID NO: 40)
3'.
```

[0135] The DNA sequence downstream of rabbit Cγ (i.e., the 3' flanking sequence of rabbit Cγ) is amplified with the following primers:

```
5' ggtaccCTCTCCCTCCCCCACGCCGCAGC   (SEQ ID NO: 41)
3'
with a 5' KpnI site and

5' atatctcagaACTGGCTGTCCCTGCTGTAGT (SEQ ID NO: 42)
ACACGG 3'
with a 5' XhoI site.
```

[0136] Human genomic DNA is isolated from human peripheral blood lymphocytes. The DNA fragment encoding human Cγ1 is amplified using the following primers:

```
5' GTCGACACTGGACGCTGAACCTCGCGG 3'  (SEQ ID NO: 43)
and

5' GGTACCGGGGGCTTGCCGGCCGTCGCAC    (SEQ ID NO: 44)
3'.
```

[0137] The fragments are digested with restriction enzymes and cloned into a Bluescript vector. Subsequently, a lox neo-cassette is inserted into the SalI site and an Hsv-tk cassette into the XhoI site. A schematic drawing of the final construct is shown in FIG. **7***a*.

EXAMPLE 3

A Vector for Replacing the Rabbit Endogenous Cκ Gene Segment with the Human Cκ Segment

[0138] Genomic DNA was isolated from rabbit fetal fibroblasts of a b5-homozygous rabbit. The DNA sequence upstream of rabbit Cκ1 (i.e., the 5' flanking sequence of rabbit Cκ1) was amplified by PCR using the following primers:

```
5' gcggccgcTGGCGAGGAGACCAAGCTGGAGA (SEQ ID NO: 45)
TCAAACG 3'
with a 5' NotI site

5' GTCGACGCAGCCCAAAGCTGTTGCAATGGGG (SEQ ID NO: 46)
CAGCG 3'.
```

[0139] The DNA sequence downstream of rabbit Cκ1 (i.e., the 5' flanking sequence of rabbit Cκ1) was amplified with the following primers:

```
5' atatggtaccGCGAGACGCCTGCCAGGGCAC (SEQ ID NO: 47)
CGCC 3'
with a 5' KpnI site

5' GGATCCCGAGCTTTATGGGCAGGGTGGGGG  (SEQ ID NO: 48)
3'.
```

[0140] Human genomic DNA was isolated from human peripheral blood lymphocytes. The DNA fragment encoding human Cκ was amplified using the following primers:

```
5' ATATGTCGACCTGGGATAAGCATGCTGTTTT (SEQ ID NO: 49)
CTGTCTGTCCC 3'

5' CTAGGTACCAGCAGGTGGGGGCACTTCTCCC (SEQ ID NO: 50)
3'.
```

The fragments were digested with restriction enzymes and cloned into a Bluescript vector. Subsequently, a lox neo-

cassette was inserted into the SalI site and an Hsv-tk cassette into the XhoI site. A schematic drawing of the final construct is shown in FIG. **7***b*.

EXAMPLE 4

Replacement of the Endogenous Cγ and Cκ Gene Segments in Rabbit Fetal Fibroblasts with the Corresponding Human Gene Segments

[**0141**] Rabbit fetal fibroblast cells are prepared by standard methods. After one passage, fibroblasts are transfected with 5 μg of the NotI-linearized targeting vector as shown in FIG. **5***a* for Cγ or FIG. **51***b* for Cκ, and are seeded in 96-well plates (2×10^3 cells/well). After a positive selection with 600 μg/ml G418 and a negative selection with 200 nM FIAU, resistant colonies are replica-plated to two 96-well plates for DNA analysis and cryopreservation, respectively. PCR and/or Southern blot analysis is performed to identify cells with the human Cγ1 gene segment integrated in the genome. The cells having the integrated human Cγ1 gene are used in rabbit cloning as described in Example 5.

EXAMPLE 5

Cloning of Rabbits

[**0142**] Mature Dutch Belton rabbits are superovulated by subcutaneous injection of follicle stimulating hormone (FSH) every 12 hours (0.3 mg×2 and 0.4 mg×4). Ovulation is induced by intravenous administration of 0.5 mg luteinizing hormone (LH) 12 hours after the last FSH injection. Oocytes are recovered by ovidual flush 17 hours after LH injection. Oocytes are mechanically enucleated 16-19 hours after maturation. Chromosome removal is assessed with bisBENZIMIDE (HOECHST 33342, Sigma, St. Louis, Mo.) dye under ultraviolet light. Enucleated oocytes are fused with actively dividing fibroblasts by using one electrical pulse of 180 V/cm for 15 us (Electrocell Manipulator 200, Genetronics, San Diego, Calif.). After 3-5 hours oocytes are chemically activated with calcium ionophore (6 uM) for 4 min (#407952, Calbiochem, San Diego, Calif.) and 2 mM 6-dimethylaminopurine (DMAP, Sigma) in CR2 medium (Specialty Media, Lavalett, N.J.) with 3 mg/ml bovine serum albumin (fatty acid free, Sigma) for 3 hours. Following the activation, the embryos are washed in hamster embryo culture medium (HECM)-Hepes five times and subsequently, cultivated in CR2 medium containing 3 mg/ml fatty-acid free BSA for 248 hours at 37.8° C. and 5% CO_2 in air. Embryos are then transferred into synchronized recipients. Offsprings are analyzed by PCR for a segment of the transgene.

EXAMPLE 6

Construction of a DNA Fragment Containing a Portion of a Rabbit Heavy Chain Locus with a Human Cγ1 Gene Segment and a VH Gene Segment Encoding a Human VH Domain Polypeptide Sequence

[**0143**] The upstream and downstream regions (i.e., the 5' and 3' flanking regions) of the rabbit heavy chain Cγ gene from an a2-allotype rabbit were sequenced. A DNA fragment (SEQ ID NO: 51) is generated by PCR using overlapping oligonucleotides wherein the DNA fragment contains from 5' to 3', a sequence derived from the 5' flanking region of the rabbit Cγ gene, the human Cγ1 gene, and a sequence derived from the 3' flanking region of the rabbit Cγ gene (FIG. **8**).

[**0144**] A genomic BAC library derived from an a2-allotype rabbit is generated by standard procedures and screened with probes specific for rabbit Cγ. A BAC clone containing rabbit heavy chain gene segments is identified. The rabbit Cγ gene on this BAC clone is replaced with the human Cγ1 gene by homologous recombination in *E. coli* using the DNA fragment of SEQ ID NO: 51 and the pET system. This replacement is accomplished by two consecutive recombination steps: first the rabbit Cγ gene segment is replaced with a marker gene; then the marker gene is replaced the human Cγ1 gene segment.

[**0145**] The modified BAC clone containing rabbit heavy chain genes and the inserted human Cγ1 gene is further modified by replacing the 3'proximal VH1 segment with A synthetic VH gene segment (FIG. **9**). This synthetic VH gene segment (SEQ ID NO: 52) is made using overlapping oligonculeotides and includes a 5' flanking sequence, a 3' flanking sequence, and a sequence coding for a polypeptide nearly identical to the human immunoglobulin heavy chain variable domain polypeptide sequence described by Huang and Stollar (*J. Immunol.* 151: 5290-5300, 1993). The coding sequence of the synthetic VH gene segment is designed based on the published sequence of a rabbit VH1 gene (a2, Knight and Becker, *Cell* 60:963-970, 1990) and is more than 80% identical to rabbit VH gene segments. The 5' and the 3' flanking sequences in the synthetic VH segment are derived from the upstream and downstream regions of the a2-allotype rabbit VH1 gene. The synthetic VH gene of SEQ ID NO: 52 is used to replace the rabbit VH1 gene on the BAC clone by homologous recombination using the pET or the redεβγ system. The modified BAC clone is amplified and purified using standard procedures.

EXAMPLE 7

Construction of a DNA Fragment Containing a Portion of a Rabbit Light Chain Locus with a Human Cκ Gene Segment and a VJ Gene Segment Encoding a Human VL Domain Polypeptide Sequence

[**0146**] The upstream and downstream regions (i.e., the 5' and 3' flanking regions) of the rabbit light chain Cκ1 gene from a b5-allotype rabbit were sequenced. A DNA fragment (SEQ ID NO: 53) is generated by PCR using overlapping oligonucleotides wherein the DNA fragment contains from 5' to 3', a sequence derived from the 5' flanking region of the rabbit Cκ1 gene, the human Cκ1 gene, and a sequence derived from the 3' flanking region of the rabbit Cκ1 gene (FIG. **10**).

[**0147**] A genomic BAC library derived from a b5-allotype rabbit is generated by standard procedures and screened with probes specific for rabbit Cκ1. A BAC clone containing rabbit light chain gene segments is identified. The rabbit Cκ1 gene on this BAC clone is replaced with the human Cκ1 gene on the DNA fragment of SEQ ID NO: 53 by homologous recombination in *E. coli* using the pET or the redεβγ system. This replacement is accomplished by two consecutive recombination steps: first the rabbit Cκ1 gene segment

is replaced with a marker gene; then the marker gene is replaced the human Cκ1 gene segment.

[0148] The modified BAC clone containing rabbit light chain genes and the inserted human Cκ1 gene is further modified by inserting a rearranged VJ DNA fragment into the J region of the rabbit light chain locus. The rearranged VJ DNA fragment encodes a human immunoglobulin variable domain polypeptide described by Pritsch et al. (*Blood* 82(10):3103-3112, 1993) and Lautner-Rieske et al. (*Eur. J. Immunol.* 22 (4), 1023-1029, 1992)) (FIG. **7**). The nucleotide sequence of the rearranged VJ fragment is designed to maximize the sequence homology at the nucleotide level to the rabbit Vkappa sequence published by Lieberman et al. (*J. Immunol.* 133 (5), 2753-2756, 1984). This rearranged VJ DNA sequence is more than 80% identical with known rabbit Vκ genes. Using overlapping oligonucleotides in PCR, the rearranged VJ DNA fragment is linked to a 5' and a 3' flanking sequence, resulting the DNA fragment of SEQ ID NO: 54 (FIG. **11**). The 5'flanking sequence is derived from 5' of a rabbit VK, the 3'flanking sequence is derived from 3' of rabbit J2. The DNA fragment of SEQ ID NO: 54 is subsequently inserted into the rabbit light chain locus by homologous recombination in *E. coli* using the pET or the redεβγ system. The insertion is performed in such a way that the rabbit light chain region containing the rabbit Vκ1 gene segment, the rabbit J1 and J2 segments, and the sequences in between, is replaced with the rearranged VJ DNA fragment. Again, this insertion is accomplished by replacement of the rabbit V to J region with a marker gene, followed by the replacement of the marker gene with the rearranged VJ DNA fragment. The modified BAC clone is amplified and purified using standard procedures.

EXAMPLE 8

Transgenic Rabbits Expressing the Humanized Immunoglobulin Light and/or Heavy Chain Transgene

[0149] Transgenic rabbits are generated as described by Fan et al. (*Pathol Int.* 49: 583-594, 1999). Briefly, female rabbits are superovulated using standard methods and mated with male rabbits. Pronuclear-stage zygotes are collected from oviduct and placed in an appropriate medium such as Dulbecco's phosphate buffered saline supplemented with 20% fetal bovine serum. The exogenous DNA (e.g., the humanized BAC clone from Example 4 and/or 5 which has been linearized prior to injection) is microinjected into the male pronucleus with the aid of a pair of manipulators. Morphological surviving zygotes are transferred to the oviducts of pseudopregnant rabbits. Pseudopregnancy is induced by the injection of human chorionic gonadotrophin (hCG). Between about 0.1-1% of the injected zygotes develop into live transgenic rabbits. Integration of the transgene in the genome is confirmed by Southern blots analysis using a probe specific for the transgene.

[0150] cDNA is prepared using RNA isolated from B cells (in blood, spleen and/or lymph nodes) of a transgenic rabbit. Primers specific for the human transgene (human CH gene segment or the synthetic humanized VH gene segment) are used to generate amplified products from cDNA. The observation of amplified products indicates that the transgene is rearranged in the transgenic animal and the rearranged transgene is transcribed in the animal. Amplified products are sequenced and the presence of donor sequences from upstream V genes indicates that the transgene introduced into the germline of the animal undergoes gene conversion.

[0151] The presence of antibodies containing human IgG and/or human kappa light chain antigenic determinants in the serum of transgenic founder rabbits is determined using an ELISA assay.

EXAMPLE 9

Production of Humanized Antibodies From Transgenic Rabbits with the Genetic Background of the Alicia and/or Basilea Rabbit Strain

[0152] The Alicia strain lacks the VH1 gene segment and therefore has an impaired Ig heavy chain expression. Transgenic founder rabbits capable of expressing humanized heavy chain molecules in the genetic background of the Alicia rabbit strain are generated, e.g., by using fetal fibroblasts established from Alicia rabbits in Examples 4-5 above, or by using zygotes from female Alicia rabbits mated with male Alicia rabbits in Example 8 above. Transgenic animals are also obtained which are homozygous for the Alicia Ig phenotype and are also homozygous for a humanized heavy chain transgene. Serum is tested in ELISA for the presence of humanized heavy chain (e.g., a human heavy chain constant region). The concentration of antibodies with humanized Ig heavy chains in these homozygous Alicia animals is substantially higher, e.g., about 10 to 100 fold higher, than that produced from a transgene integrated in the genome of wild type (non-Alicia) rabbits.

[0153] The Basilea strain does not express κ1 light chain and in its place exclusively express the κ2 and λ light chains. Transgenic founder rabbits capable of expressing humanized light chain molecules in the genetic background of the Basilea rabbit strain are generated, e.g., by using fetal fibroblasts established from Basilea rabbits in Examples 4-5 above, or by using zygotes from female Basilea rabbits mated with male Basilea rabbits in Example 8 above. Transgenic animals are obtained which are homozygous for the Basilea light chain phenotype, and are also homozygous for a humanized light chain transgene. Serum is tested in ELISA for the presence of the humanized light chain. The concentration of the humanized light chain in the homozygous Basilea animals is substantially higher, about 10-100 fold higher, than the concentration of a humanized light chain in a transgenic rabbit with the wild type (non-Basilea) genetic background. Transgenic founder rabbits are mated with each other to generate transgenic rabbits with the following traits: (1) having at least one humanized light chain transgene, (2) having at least one humanized heavy chain transgene, (3) homozygous for the Alicia heavy chain locus, and (4) homozygous for the Basilea light chain locus.

EXAMPLE 10

Construction of a DNA Fragment Containing a Modified Chicken Light Chain Locus Having a Human Clambda2 Gene Segment and a VJ Gene Segment Encoding a Human VL Domain

[0154] A genomic BAC library derived from a jungle fowl chicken was screened with radiolabeled probes specific for chicken light chain Clambda and chicken Vpsi25 (the V gene segment at the very 5' end of the light chain locus). A

BAC clone containing the entire lambda light chain locus was identified. The chicken Cλ gene on this BAC clone is replaced with the human Cλ2 gene by homologous recombination in *E. coli* using the pET system (Zhang et al., *Nat. Biotechnol.* 18(12):1314-7, 2000) as follows.

[0155] A first DNA fragment containing a kanamycin selection cassette was generated by PCR using primers specific for Tn5 gene. The 5' primer (5'catacacagccatacatacgcgtgtggccgctctgcctctctct-tgcaggTATGGACAGCAAGCGAACCG 3', SEQ ID NO: 55) was designed to include 50 bp at the 5' end (lower case), derived from the 5' flanking region of the chicken light chain Cλgene. The 3' primer (5'atcagggtgacccctacgttacactcct-gtcaccaaggagtgggagggacTCAGAAGAACTCGTCAAGA AG3', SEQ ID NO: 56) was designed to include about 50 bp at the end (lower case), derived from the 3' flanking region of the chicken light chain Cλ) gene.

[0156] A second DNA fragment (SEQ ID NO: 57) was synthesized using overlapping oligonucleotides wherein the DNA fragment contains from 5' to 3', a sequence derived from the 5' flanking region of the chicken light chain Clambda gene, the human Clambda2 gene, and a sequence derived from the 3' flanking region of the chicken Clambda gene (FIG. **12**).

[0157] *E. coli* cells of the chicken light chain BAC clone were transformed with a recombination plasmid expressing the recE and recT functions under an inducible promotor. Cells transformed with the recombination plasmid were then transformed with the first DNA fragment above and selected afterwards in media containing kanamycin. Clones resistant to kanamycin were identified, and the replacement of the chicken Cλ segment by the kanamycin selection cassette via homologous recombination was confirmed by restriction enzyme digest.

[0158] In the second homologous recombination step, cells positive for the kanamycin selection cassette were transformed with the second DNA fragment above. Transformed cells were screened for the loss of kanamycin resistance as indicative of the replacement of the kanamycin selection cassette by the human Cλ2 gene. The exchange was confirmed by restriction enzyme digest and/or sequence analysis.

[0159] The ET cloning procedure is summarized in FIG. **13**.

[0160] The BAC clone containing the chicken light chain locus and the inserted human Clambda2 gene segment was further modified by inserting a rearranged VJ DNA fragment. The rearranged VJ DNA fragment encodes a human immunoglobulin variable domain polypeptide described by Kametani et al. (*J. Biochem.* 93 (2), 421-429, 1983) as IG LAMBDA CHAIN V-I REGION NIG-64 (P01702) (FIG. **14**). The nucleotide sequence of the rearranged VJ fragment was so designed as to maximize the sequence homology at the nucleotide level to the chicken Vlambda1 sequence published by McCormack et al. (*Cell* 56, 785-791, 1989). This rearranged VJ DNA sequence is more than 80% identical with known chicken light chain V genes. The rearranged VJ DNA fragment was linked to a 5' flanking sequence and a 3' flanking sequence, resulting in the DNA fragment of SEQ ID NO: 58 (FIG. **14**). The 5' flanking sequence was derived from 5' of chicken Vlambda1, and the 3'flanking sequence was derived from 3' of chicken J. The DNA fragment of SEQ ID NO: 58 was subsequently inserted into the chicken light chain locus in *E. coli* using the pET system as shown in FIG. **15**. The insertion was performed in such a way that the region on the chicken light chain locus from the 5' end of the chicken Vlambda1 gene segment to the 3' end of the chicken J region was replaced with the rearranged, synthetic VJ DNA fragment. Again, this insertion wais accomplished by the replacement of the chicken V-J region with a marker gene, followed by the replacement of the marker gene with the rearranged VJ DNA fragment. The modified region of the chicken light chain locus is shown in FIG. **15**. The modified BAC clone was amplified and purified using standard procedures.

EXAMPLE 11

Construction of a DNA Fragment Containing a Portion of a Chicken Heavy Chain Locus With a Human Cγ1 Gene Segment and a VH Gene Segment Encoding a Human VH Domain Polypeptide Sequence

[0161] A jungle fowl chicken genomic BAC library was generated by standard procedures and screened with probes specific for chicken Cγ. A BAC clone containing chicken heavy chain gene segments is identified. The upstream and downstream regions (i.e., the 5' and 3' flanking regions) of the heavy chain Cγ gene are sequenced. The chicken Cγ gene on this BAC clone is replaced with the human Cγ1 gene by homologous recombination in *E. coli* using the pET system as follows.

[0162] A first DNA fragment containing a kanamycin selection cassette is generated by PCR using primers specific for Tn5 gene. The 5' and 3' primers are designed to include about 50 bp at the end, derived from the 5' and 3' flanking regions of the chicken heavy chain Cγ gene.

[0163] A second DNA fragment is generated by PCR using overlapping oligonucleotides wherein this second DNA fragment contains from 5' to 3', a sequence of about 50 bp derived from the 5' flanking region of the chicken Cγ gene, the human Cγ1 gene, and a sequence of about 50 bp derived from the 3' flanking region of the chicken Cγ gene.

[0164] *E. coli* cells of the chicken CY BAC clone are transformed with a recombination plasmid expressing the recE and recT functions under an inducible promotor. Cells transformed with the recombination plasmid are further transformed with the first DNA fragment and selected in media containing kanamycin. Clones resistant to kanamycin are identified, and the replacement of the chicken CY segment by the kanamycin selection cassette via homologous recombination is confirmed by restriction enyme digest.

[0165] In the second homologous recombination step, cells positive for the kanamycin selection cassette are now transformed with the second DNA fragment described above. Transformed cells are screened for loss of kanamycin resistance as indicative of the replacement of the kanamycin selection cassette by the human Cγ1 gene. The exchange is confirmed by restriction enzyme digest and/or sequence analysis.

[0166] The BAC clone containing the inserted human Cγ1 gene is further modified by replacing the 3'proximal VH1

segment (i.e., the 3'proximal VH1 gene in the V region) with a synthetic VH gene segment. This synthetic VH gene segment is designed based on the published sequence of a chicken VH1 gene (Arakawa et al., *EMBO J* 15(10): 2540-2546, 1996). The synthetic gene segment is more than 80% identical to chicken VH gene segments and encodes an amino acid sequence that is identical to the amino acid sequence of a human immunoglobulin heavy chain variable domain polypeptide described by Matthyssens and Rabbitss (in Steinberg CM and Lefkovits I, (eds). *The Immune System:* 132-138, S. Karger, NY 1981). This synthetic VH segment including 5' and 3' flanking sequences is synthesized by PCR using overlapping oligonucleotides. The 5' and the 3' flanking sequences are derived from the upstream and downstream regions of chicken VH1 gene. This synthetic VH segment is used to replace the chicken VH1 gene on the BAC clone by homologous recombination using the pET system. The modified BAC clone is amplified and purified using standard procedures.

EXAMPLE 12

Transgenic Chicken Expressing the Humanized Immunoglobulin Light and/or Heavy Chain Transgenes

[0167] The production of transgenic chicken is carried out using techniques as described by Etches et al., *Methods in Molecular Biology* 62: 433-450; Pain et al., *Cells Tissues Organs* 1999; 165(34): 212-9; Sang, H., "Transgenic chickens—methods and potential applications", *Trends Biotechnol* 12:415 (1994); and in WO 200075300, "Introducing a nucleic acid into an avian genome, useful for transfecting avian blastodermal cells for producing transgenic avian animals with the desired genes, by directly introducing the nucleic acid into the germinal disc of the egg".

[0168] Briefly, the modified BAC clones are linearized and mixed with a transfection reagent to promote uptake of DNA into cells. The formulations are injected into a multicell stage chicken embryo in close proximity to the germinal disc. The window in the egg shell is closed and the eggs are incubated. After hatching chimeric chickens are identified by PCR and Southern blot analysis using transgene specific sequences. Integration of the transgene in the genome is confirmed by Southern blots analysis using a probe specific for the transgene. Heavy and light chain transgenic animals are bred with each other to generate transgenic chickens expressing antibodies having humanized heavy and light chains.

[0169] cDNA is prepared using RNA isolated from B cells (in blood, spleen and/or lymph nodes) from transgenic chickens. Primers specific for the human transgene (e.g., human CH gene segments and/or the synthetic humanized VH gene segments) are used to generate amplified products from cDNA. The observation of amplified products indicates that the transgene is rearranged in the transgenic animal and the rearranged transgene is transcribed in the animal. Amplified products are sequenced and the presence of donor sequences from upstream V genes indicates that the transgene introduced into the germline of the animal undergoes gene conversion.

[0170] The presence of antibodies containing human IgG and/or human kappa light chain antigenic determinants in the serum of transgenic chickens is determined using an ELISA assay.

EXAMPLE 13

Production of Functional Humanized Antibodies in Transgenic Chicken with the Agammaglobulinemic Phenotype

[0171] Transgenic chickens with the following traits are produced: (1) having at least one humanized light chain transgene, (2) having at least one humanized heavy chain transgene, and (3) homozygous for the agammaglobulinemic phenotype. These animals produce antibodies into the blood and eggs, and antibodies can be purified from either source. In general, antibody concentrations in the eggs are about 5% to 50% of antibodies concentration in the blood. Animals that contain humanized antibodies at high levels in eggs can be selected and bred to produce offspring. Alternatively, transgenic animals can be generated that specifically secrete humanized antibodies into their eggs.

EXAMPLE 14

Generation of Transgenic Chickens Expressing Humanized Immunoglobulin

[0172] Chicken embryonic stem cells are isolated and cultured as described by Pain et al. (*Development* 122, 2339-2348; 1996). Chicken embryos are obtained from eggs immediately after they are laid. The entire blastoderm is removed by gentle aspiration, embryos are slowly dissociated mechanically and cells are seeded in ESA complete medium on inactivated STO feeder cells. ESA medium is composed of MEM medium containing 10% FCS, 2% chicken serum, 1% bovine serum albumin, 10 ng/ml ovalbumin, 1 mM sodium pyruvate, 1% non-essential amino acids, 1 μM of each nucleotide adenosine, guanosine, cytidine, uridine, thymidine, 0.16 mM β-mercaptoethanol, ESA complete medium is supplemented with 10 ng/ml bFGF, 20 ng/ml h-IGF-1, 1% vol/vol avian-SCF and 1% vol/vol h-LIF, 1% vol/vol h-IL-11. Cell cultures are incubated wt 37° C. in 7.5 CO_2 and 90% humidity. After 48 hours fresh blastodermal cells are added to the culture in half of the original volume of ESA complete medium. After an additional incubation for three days, the culture medium is partially (50%) replaced with fresh ESA complete medium, and totally every day thereafter. For cell harvesting, cultures are washed with PBS and incubated in a pronase solution (0.025% w/v). Dissociated cells are transfected with various linearized transgenic constructs containing a humanized Ig locus. Transfected cells are incubated with STO feeder cells (as described above) in the presence of selective antibiotics. Cells are transferred onto fresh feeder cells twice per week. Antibiotic resistant cells are isolated and the integration of a humanized Ig gene fragments at a random site or at the corresponding chicken immunoglobulin gene loci is confirmed by PCR.

[0173] Subsequently, genetically modified cells are injected into recipient embryos. As recipient embryos, freshly laid eggs are irradiated (6Gy—Cobalt source). Between 100 to 200 genetically modified cells are injected into the subgerminal cavity using a micropipet. The window in the egg shell is closed and the eggs are incubated. Somatic chimerism of hatched chickens is evaluated by PCR. Germline chimerism is assessed by mating of somatic chimeras.

EXAMPLE 15

Immunization of Transgenic Animals

[0174] Genetically engineered chickens are immunized intramuscularly with purified Hepatitis B surface antigen (HBsAg) (5 μg in incomplete Freund's adjuvant) on day 0, 14 and day 28. On day 35 animals are bled and serum is prepared. ELISA plates (NUNC, Denmark) are coated with 1 μg/ml HBsAg in PBS for 1 hour at room temperature. Subsequently, available binding sites are blocked by incubation with 1% non-fat dry milk (NFM) in PBS (300 μl/well). Chicken serum is diluted in PBS/1% NFM and added to the coated wells. After an incubation of 1 hour, the plates are washed 3 times with PBS/0.05% Tween 20 and bound Ig is detected using goat anti-human Ig conjugated with horseradish peroxidase. Conjugated goat antibody is detected using o-phenylenediamine dihydrochloride (Sigma) at 1 mg/ml. The colorimetric reaction is stopped by addition of 1 M HCl solution and the absorbance is measured at 490 nm. As a control, serum from non-immunized chicken is used. Serum from non-immunized chickens does not react with HBsAg. At a dilution of 1:250 the optical density measured in uncoated and HBsAg coated wells is below 0.2. In contrast, serum from immunized chickens contains humanized antibodies reactive with HBsAg. At a serum dilution of 1:250 the measured optical density is 2.3. Upon further dilution of the serum the measured optical density declines to 0.1 (at a dilution of 25600). No antibodies reactive with a goat anti-chicken IgG-HRP conjugate can be detected. This demonstrates that the genetically engineered chickens produce humanized anti-HBsAg antibodies following immunization.

[0175] Genetically engineered rabbits are immunized intramuscularly with purified Hepatitis B surface antigen (HBsAg) (10 μg in incomplete Freund's adjuvant) on day 0 and day 14. On day 28 animals are bled from the ear and serum is prepared. ELISA plates (NUNC, Denmark) are coated with 1 μg/ml HBsAg in PBS for 1 hour at room temperature. Subsequently, available binding sites are blocked by incubation with 1% non-fat dry milk (NFM) in PBS (300 μl/well). Rabbit serum is diluted in PBS/1% NFM and added to the coated wells. After an incubation of 1 hour, the plates are washed 3 times with PBS/0.05% Tween 20 and bound Ig is detected using goat anti-human Ig conjugated with horse-radish peroxidase. Conjugated goat antibody is detected using o-phenylenediamine dihydrochloride (Sigma) at 1 mg/ml. The calorimetric reaction is stopped by addition of 1 M HCl solution and the absorbance is measured at 490 nm. As a control serum from non-immunized rabbits is used. Serum from non-immunized rabbits does not react with HBsAg. At a dilution of 1:100 the optical density measured in uncoated and HBsAg coated wells is below 0.4. In contrast, serum from immunized rabbits contains partially human antibodies reactive with HBsAg. At a serum dilution of 1:100 the measured optical density is 2.8. Upon further dilution of the serum the measured optical density declines to 0.2 (at a dilution of 25600). No antibodies reactive with a goat anti-rabbit IgG-HRP conjugate can be detected. This demonstrates that the genetically engineered rabbits produce humanized anti-HBsAg antibodies following immunization.

EXAMPLE 16

Complement Mediated Cytotoxicity of Virus Infected Cell Line Using Humanized Antibodies

[0176] A human liver carcinoma cell line expressing HBsAg is labeled with 0.1 mCi ^{51}Cr in 100 ul PBS for 1 hr at 37° C. Two thousand ^{51}Cr-lableled cells are incubated with serum from genetically engineered rabbits or chickens expressing anti-HbsAg humanized immunoglobulins. After two hours at 37° C. the release of ^{5}Cr into the supernatant is determined by measuring radioactivity using a scintillation counter. For the determination of maximum release, 1% Triton X100 is added. The degree of cell lysis is calculated as follows: % Lysis=CPM experimental±CPM#spontaneous/CPM# total±CPM spontaneous. Incubation of labeled cells with serum (diluted 1:30) from non-immunized rabbits does not result in cell lysis (<10%). However, incubation of cells with serum from immunized rabbits causes 80% cell lysis. Inactivation of complement in the serum by heat treatment (56° C. for 30 minutes) renders the serum from immunized rabbits inactive. These results demonstrate that humanized antibodies produced by genetically engineered rabbits bind to HBsAg-positive cells and cause complement dependent lysis.

EXAMPLE 17

Immunization of Transgenic Animals against *Staphylococcus aureus*

[0177] Genetically engineered chickens are immunized intramuscularly with a recombinant fragment of the *Staphylococcus aureus* collagen adhesin protein (100 μg in incomplete Freund's adjuvant) on day 0, 14 and day 28. On day 35 animals are bled and serum is prepared. ELISA plates (NUNC, Denmark) are coated with 2 μg/ml collagen adhesin protein in PBS for 1 hour at room temperature. Subsequently, available binding sites are blocked by incubation with 1% non-fat dry milk (NFM) in PBS (300 μl/well). Chicken serum is diluted in PBS/1% NFM and added to the coated wells. After an incubation of 1 hour, the plates are washed 3 times with PBS/0.05% Tween 20 and bound Ig is detected using goat anti-human Ig conjugated with horseradish peroxidase. Conjugated goat antibody is detected using o-phenylenediamine dihydrochloride (Sigma) at 1 mg/ml. The calorimetric reaction is stopped by addition of 1 M HCl solution and the absorbance is measured at 490 nm. As a control, serum from non-immunized chicken is used. Serum from non-immunized chickens does not react with collagen adhesin protein. At a dilution of 1:250 the optical density measured in uncoated and collagen adhesin protein coated wells is below 0.2. In contrast, serum from immunized chickens contains humanized antibodies reactive with collagen adhesin. At a serum dilution of 1:250 the measured optical density is 2.3. Upon further dilution of the serum the measured optical density declines to 0.1 (at a dilution of 25600). No antibodies reactive with a goat anti-chicken IgG-HRP conjugate can be detected. This demonstrates that the genetically engineered chickens produce humanized anti-Staph. aureus collagen adhesin antibodies following immunization.

[0178] Genetically engineered rabbits are immunized intramuscularly with recombinant fragment of the *Staphylococcus aureus* collagen adhesin protein (100 μg in incom-

plete Freund's adjuvant) on day 0 and day 14. On day 35 animals are bled and serum is prepared. ELISA plates (NUNC, Denmark) are coated with 2 μg/ml collagen adhesin protein in PBS for 1 hour at room temperature. Subsequently, available binding sites are blocked by incubation with 1% non-fat dry milk (NFM) in PBS (300 μl/well). Rabbit serum is diluted in PBS/1% NFM and added to the coated wells. After an incubation of 1 hour, the plates are washed 3 times with PBS/0.05% Tween 20 and bound Ig is detected using goat anti-human Ig conjugated with horseradish peroxidase. Conjugated goat antibody is detected using o-phenylenediamine dihydrochloride (Sigma) at 1 mg/ml. The colorimetric reaction is stopped by addition of 1 M HCl solution and the absorbance is measured at 490 nm. As a control, serum from non-immunized rabbit is used. Serum from non-immunized rabbits does not react with collagen adhesin protein. At a dilution of 1:250 the optical density measured in uncoated and collagen adhesin protein coated wells is below 0.2. In contrast, serum from immunized rabbits contains humanized antibodies reactive with collagen adhesin. At a serum dilution of 1:250 the measured optical density is 2.3. Upon further dilution of the serum the measured optical density declines to 0.1 (at a dilution of 25600). No antibodies reactive with a goat anti-rabbit IgG-HRP conjugate can be detected. This demonstrates that the genetically engineered rabbits produce humanized anti-Staph. aureus collagen adhesin antibodies following immunization.

EXAMPLE 18

Protection Against *Staphylococcus Aureus* Infection in a Mouse Model

[0179] Naive mice are passively immunized i.p. on day -1 with 16 mg of the immunoglobulin fraction containing antibodies specific for the *S. aureus* collagen adhesin protein (from Example 17) or with the immunoglobulin fraction from non-immunized animals. On day 0, the mice are challenged i.v. with 4×10^7 CFU *S. aureus* per mouse and mortality is monitored over the next 7 days. Mortality rate in the control groups is 80% and 10% in the group treated with the immunoglobulin fraction containing antibodies specific for the *S. aureus* collagen adhesin protein. The data indicate that anticollagen adhesin antibodies can protect mice against lethal *S. aureus* challenge.

EXAMPLE 19

Antigen-Specific Hybridomas Made from Transgenic Animals

[0180] Transgenic animals are immunized with an antigen (e.g., KLH, human red blood cells or sheep red blood cells). Spleen cells are removed at various times after immunization and fused with myeloma cell lines derived from rabbit and chicken, respectively. After fusion cells are plated into 96 well plates and supernatants are tested for the presence of humanized antibodies. To demonstrate that the antibodies contain human immunoglobulin sequences, hybridomas are stained with fluorescent-labeled antibodies reactive with human heavy and light chain immunoglobulins. Limiting dilution is conducted to purify hybridomas to monoclonality.

EXAMPLE 20

Evaluation of Immunogenicity

[0181] Serum samples are collected from five cynomologous monkeys on day 0. Subsequently, a purified partially human polyclonal antibody preparation (5 mg/kg) is administered into five cynomologous monkeys by intravenous administration. The administration is repeated six times in bi-weekly intervals. Monkeys are monitored closely for any side-effects (e.g., anaphylactic shock, reflected by an elevated body temperature). After seven months serum is collected from blood samples. Affinity resins containing purified human IgG or partially human IgG are produced by standard procedure using CNBr-activated Sepharose. Monkey serum samples (3 ml) are added to the IgG-affinity resin (4 ml) containing 10 mg human or partially human IgG. Subsequently, the columns are washed with PBS. Bound monkey immunoglobulin is eluted from the column with 0.1M glcyin/HCl pH2.5 and dialyzed 2 times against PBS. The protein content of the eluted fractions is determined using the BCA assay using human IgG as a standard. The total amounts of protein in these fractions demonstrate that therapy with partially human IgG does not lead to a significant antibody response in the treated animals.

EXAMPLE 21

Treating Animals Using Humanized Antibodies

[0182] Humanized polyclonal immunoglobulins are purified from the serum of genetically engineered rabbits, or from egg yolk of genetically engineered chickens, by ammonium sulfate precipitation and ion exchange chromatography. SCID-mice are injected with one million human liver carcinoma cells expressing HBsAg. Subsequently, 25 μg immunoglobulin is injected peritoneally once per day. Animals treated with antibodies isolated from non-immunized rabbit serum die after about 60 days. This is similar to untreated recipients of liver carcinoma cells. In contrast, mice treated with antibodies isolated from immunized rabbit serum survive for more than 150 days. This demonstrates that human antibodies produced in genetically engineered rabbits are capable of eliminating human carcinoma cells from SCID-mice.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 58

<210> SEQ ID NO 1
<211> LENGTH: 29
<212> TYPE: DNA

-continued

<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:primer

<400> SEQUENCE: 1

cgcaagcttc ctacacgtgt gtggtgatg 29

<210> SEQ ID NO 2
<211> LENGTH: 29
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:primer

<400> SEQUENCE: 2

cgcaagctta agatggwgat ggtsgtcca 29

<210> SEQ ID NO 3
<211> LENGTH: 1714
<212> TYPE: DNA
<213> ORGANISM: cow

<400> SEQUENCE: 3

cctacacgtg tgtggtgatg cacgaaactt tacggaatca ctacaaagag aagtccacct 60

cgaggtctcc gggtaaatga gcctcgcgcc gctgatctag tggacgttcc ctcatccacc 120

caccctccc cccaccccgg gctccaggtc cagccagggc gccctagccc ctccctgtgt 180

gcattcctcc tgggccgccg tgaataaagc acccaggccg ccctgggacc ctgcaacgct 240

gtgctggttc tttccgaggc agagccctgg tggccgccag gcctgcgggg gtgggctgag 300

ccgactctgg gccactttgt tcagcatctg tgggggagct gaccccactc cgggccagac 360

acacagtgag tgggtccagc aggccacctg ggggctgccc aaggccacag aggggcttgg 420

ccagaggcac agctccacgg tcccctccag ccaccacctg ctgggccggc ctctggacag 480

gaaccgggga agcccccgag accctcaggg attgaggccc aatgcttccc gcctctgctc 540

cagcccacgc tgtggggcag ggccacatcc ttgtccccag gcccctgtcc ttgggtgtcc 600

agagtccttg tgtccactct gggcctgcct ggagccacgc atggccaggg ggtggccctg 660

cttcaccctc aggctcccaa ggtcaggcct cgccctccct cggccaggag gctctgcccg 720

gctctccctg cccagggcca ggcctgtgcg cccatgggga ggtcatccct gtgcctgaaa 780

ggggtccagg ccgagagccc tgaatgtcca gggcagggac ctagctgctc cctgtggaca 840

cggagcccag agccacagac aacaagcccc agccccgcac gcacacgaga cagcccgcac 900

ccagcctcct ccacacgcac tcaggtgtac atgcgcacat gagcacactt caccccgtca 960

cacccacaca cctacacaca ctcaggtctc gcactcgggg acccatgggg tgaccccacg 1020

ggcccagacc agagctgggt cttgtgagcc ctccctgtgg acaccagctg ggccccaccc 1080

tccagcgccc atgggctgct cagcggccct ttcccacact gaccacactg accaggtcag 1140

acatccgttc cttgcctccc ctgggacacc cacgcccctc cctagcaggc tgagatcccc 1200

cctcagcccc tcgtcctggc agcctcaccc ctcgggcaca gcacccctca ggcccggtgc 1260

tgtcagccct ccctccccgg gggcagggcc caggaacgtg cgctctgctg accctcccag 1320

ctccaggcct ggcccccagg gcagaggagg ccaggaactg agcctctgtc ctgtggggag 1380

gtagggtcag ggtcccagct cagggcacag ctcaggatgg gagcaggacc ccacaggcca 1440

-continued

ggcccagata gcagccaggg ctggaggggt tggggctggg gctgggcccc agagactgac 1500

ctcaggtgac ccctgcctgg cccatgggga gatcacgcca ccttcccccc acccagaggg 1560

agccctgccc taccccagtg accctgccca gccctccgtg ggcagacaca gcactgacca 1620

cccctccctg tgcagacttg ctgctggagg aggagatctg tgcggacgac ctggatgggg 1680

agctggacgg gctctggacc accatctcca tctt 1714

<210> SEQ ID NO 4
<211> LENGTH: 1704
<212> TYPE: DNA
<213> ORGANISM: cow

<400> SEQUENCE: 4

cctacacgtg tgtggtgatg cacgaggccc tgcacaatca ctacacgcag aagtccacct 60

ctaagtctgc gggtaaatga gcctcacgtc cctgcaccag caagccctca cccagcccac 120

cctccccggg ctccaagtcc agccaggacg ccctagcccc tccctgtgtg cattcctcct 180

gggccgccgt gaataaagca cccaggccac cctgggaccc tgcaacgctg tgctggttct 240

ttccgaggca gagccctggt ggccgccagg cctgcagggg tgggctgagc cgactctggg 300

ccactttgtt cagcatctgt gggggagctg accccgctcc gggccagaca cacagtgagt 360

gggtccagca ggccacctgg gggctgcccg aggccacgga ggggcttggc cagaggcgta 420

cctccacggc cccctccagc caccacctgc tgggccggcc tctggacagg aaccggggaa 480

gcccccgaga ccctcaggga ttgaggccca atgcttcccg cctctgctcc agcccacgct 540

gtggggcagg gccacatcct tgtccccagg cccctgtccc tgggtgccca gagtccttgt 600

gtccactctg ggcctgcctg gagccacgcg tggccggggg atggccctgc tccaccctca 660

ggctcccaag gtcaggcctc gccctccctc agccaggagg ctctgcccgg ctctccctgc 720

ccagggccag gcctgtgcgc ccatggggag gtcatccctg tgcctgaaag ggctccaggc 780

cgggagccct gaatgtccag ggcagggacc tagctgctcc ctgcagacac ggagcccaga 840

gccacagaca acaagcccca gccccgcacg cacacaagac agcccgcacc cagcctcctc 900

cacacgcact caggtgtgca tccgcacatg agcacacttc accccgtcac acccacacgc 960

ctacacacac tcaggtctcg cactcgggga cccatggggt gaccccacag gcccagaccc 1020

agagctgggt cttgtgagcc ctccctgtgg acaccagctg gtccccaccc tccagcgccc 1080

atgggctgct cagtggccct ttcccacact gaccacactg accaggtcag acatccgttc 1140

cttgcctccc ctggggcacc cacgcccctc cctagcaggc tgagatcccc cctcagcccc 1200

tcgtcctggc accctcaccc ctcaggcaca gggacacagc ccggcgctgt ctgccctccc 1260

tccctggggg cagggcccag gctcacatgc tctgctgacc ctcccggctc caggcctggc 1320

ccccagggca gaggaggcca ggaactgagc ctctgtcctg gggggaggtg gggtcagggc 1380

cccagctcag ggcacagctc aggatgggaa caggacacca caggccaggc ccagacagtg 1440

gccagggctg gaggggtggg gtctggggct ggggcccaga gactgacctc aggtgatccc 1500

tgcccagccc atgggggggat cctgccacct tccccccacc cagagggagc cctgccccga 1560

ggccctgatg atgccaccca gccccccgtg ggcagacaca gcactgacca cccctccctg 1620

tgcagacctg ctgctggagg aggagatctg tgcggacgcc caggacgggg agctggacgg 1680

gctctggacg accatcacca tctt 1704

-continued

<210> SEQ ID NO 5
<211> LENGTH: 1704
<212> TYPE: DNA
<213> ORGANISM: cow

<400> SEQUENCE: 5

cctacacgtg tgtggtgatg cacgaggccc tgcacaatca ctacacgcag aagtccacct 60

ctaagtctgc gggtaaatga gcctcacgtc cctgcaccag caagccctca cccagcccac 120

cctccccggg ctccaggtcc agccaggacg ccctagcccc tccctgtgtg cattcctcct 180

gggccgccgt gaataaagca cccaggccgc cctgggaccc tgcaacgctg tgctggttct 240

ttccgaggca gagccctggt ggccgccagg cctgcggggg tgggctgagc cgactctggg 300

ccactttgtt cagcatctgt gggggagctg accccactcc gggccagaca cacagtgagt 360

gggtccagca ggccacctgg gggctgccca aggccacaga ggggcttggc cagaggcaca 420

gctccacggt cccctccagc caccacctgc tgggccggcc tctggacagg aaccggggaa 480

gcccccgaga ccctcaggga ttgaggccca atgcttcccg cctctgctcc agcccacgct 540

gtggggcagg gccacatcct tgtccccagg cccctgtcct tgggtgtcca gagtccttgt 600

gtccactctg ggcctgcctg gagccacgca tggccagggg gtggccctgc ttcaccctca 660

ggctcccaag gtcaggcctc gccctccctc ggccaggagg ctctgcccgg ctctccctgc 720

ccagggccag gcctgtgcgc ccatggggag gtcatccctg tgcctgaaag gggtccaggc 780

cgagagccct gaatgtccag ggcagggacc tagctgctcc ctgtggacac ggagcccaga 840

gccacagaca acaagcccca gccccgcacg cacacgagac agcccacacc ccgcctcctc 900

cacacgcact caggtgtgca tccgcacatg agcacacttc accccatcac acccacacgc 960

ctacacacac tcaggtctcg cactcgggga cccatggggt gaccccacag gcccagaccc 1020

agagctgggt cttgtgagcc ctccctgtgg acaccagctg gtccccaccc tccagcgccc 1080

gtgggctgct cagcggtcct ttcccacact gaccacactg accaggtcag acatccgttc 1140

cttgcctccc ctggggcacc catgcccctc cctagcaggc tgagatcccc cctcagcccc 1200

tcgtcctggc accctcaccc ctcaggcaca gggacacagc ccggtgctgt ctgccctccc 1260

tccctggggg cagggcccag gctcacatgc tctgctgacc ctcccagctc caggcctggc 1320

ccccagggca gaggaggcca ggaactgagc ctctgtcctg gggggaggtg gggtcagggc 1380

cccagctcag ggcacagctc aggatgggag caggacacca caggccaggc ccagacagtg 1440

gccagggctg gaggggtggg gtctggggct gggccccaga gaatgacctc aggtgatccc 1500

tgcccagccc atgggggggat cctgccacct tccccccacc cagagggagc cctgccccga 1560

ggccctgatg atgccaccca gccccccgtg ggcagacaca gcactgacca cccctccctg 1620

tgcagacctg ctgctggagg aggagatctg tgcggacgcc caggacgggg agctggacgg 1680

gctctggacc accatcacca tctt 1704

<210> SEQ ID NO 6
<211> LENGTH: 29
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:primer

<400> SEQUENCE: 6

-continued

cgcggatccc ctacgcgtgt gtggtgatg 29

<210> SEQ ID NO 7
<211> LENGTH: 29
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:primer

<400> SEQUENCE: 7

cgcggatcca ccgaggagaa gatccactt 29

<210> SEQ ID NO 8
<211> LENGTH: 2842
<212> TYPE: DNA
<213> ORGANISM: sheep

<400> SEQUENCE: 8

cctacgcgtg tgtggtgatg cacgaggctc tacacaacca ctacacacag aagtcgatct 60

ctaagcctcc gggtaaatga gccacatgcc cccgcaccag caagccctca cccagcccgc 120

cctccccggg ctccaggtcc agccaggacg ccctagcccc tccctgtgtg catgcctcct 180

gggccgccat gaataaagca cccaggccgc cctgggaccc tgcaacgctg tgcttgttct 240

ttccgaggca gagccctggt gaccgccagg cctgcggggg gtgggctgag cccactctgg 300

gccgcttggt tcagcatctg tgggggcgct gacccctctc cgggccagac acacagtgag 360

tgggtccggc agggcacctg ggggctgccc gaggcctcgg aggggcttgg ccagaggcgc 420

agcttcacgg ccccctccag ccaccacatt ctgggccaga ctctgggcag gaacgggggа 480

agcccccgac acctcaggga ttgaggccca acgcttcccg cctctgctcc agcccacgct 540

gaggggcagg gccgcggcct tgtccccagg cccctgttcc tgggtgccca gagtccgtgt 600

gtccactctg ggcctgcctg gagccagact ggcccagggg gaggccctgc ttcaccctca 660

ggctcccgag gtcaggcatc atcctcgtcg gccagtagct ctgcctggct ctctctgccc 720

ggggccaagc ctgtgtgccc atggggaggt cgtccctgtg cctgaaaagg gcccaggctg 780

ggagccctga acgtccaggg cagggaccta gctgctccct ggggacactg agcccagagc 840

cccagacacc aagccccagc cccgcacgca cacgagacag cccacaccca gcgtcctcca 900

cacgcactca ggcgtccacc cgcacacaag catgcttcac ccccgtcaca cacccacatg 960

cctgcacaca ctcaggtctc acgctccggg acccatggag tgatcccacg ggcccagacc 1020

cagagctggg tctcatgagc cctccctgtg gacaccagct ggtccccatt ctccagcgcc 1080

cttgggctgc tcagtggccc tttcccacac tgaccacact gaccaggtca gacatccttc 1140

ctcgcctccc ctggggcacc cacgcccctc cctcgcaggc tgagacccca cctcagcccc 1200

tcgtcctggc accctcaccc ctcgggcaca gggacacagc ccggcactgt ctgccctccc 1260

tctcggggac agagcccagg cacgtgtgct ctgctgagcc tcccggctcc aggcctggcc 1320

cccagggcag aggaggccag gaattgagcc tctgtcctgc ggggaggtgg ggtcagggcc 1380

ccagctcagg gcacagctca ggatgggagc aggaccccac aggccaggcc cagacagtgg 1440

ccagggctgg ggctggggct ggggcccaga gactgacctc aggtgacccc tgcccggccc 1500

atgggggatc acaccgccat ccccccccgcc gcagagggag ccctgccccg aagccccgat 1560

ggccccgccc agcccccccgt gggcagacac agcactgacc cccctccctg tgcagatctg 1620

-continued

ctgctggagg aggagagctg tgcggacgcc caggacgggg agctggacgg gctctggacg 1680

actatctcca tcttcatcac gcccttcctg ctcagcgtct gctacagcgc caccgtgacc 1740

ctcttcaagg tgggggtcca ccctgctggg ccctcgggcc ccctctctgt ccccagggtc 1800

cccgcagagt ccctccctgc ccctcactgt ccctccctgt ccctctctgt ccctctctgt 1860

ccctctctgt ccctctctgt ccgttcattt tcccttcacc gtaagcttga gacagattgg 1920

ggtcatttca gagggcgtct gaagagtctc tgtgccgcac gcctcccttc atgtcagtgg 1980

ggagaattca gcaagggtgg agtgctgggt gagaaatgag gcttgcggcg ctcacgagca 2040

gtgatggggc actgctgctc cctgagacct gcgcggacac cgttttccat cgcaggagaa 2100

gcgggcaagg gaaaacgccc tcttggtctc tcttgagtaa atgtcgcgtt ttggtcatca 2160

gtccctcccc cagtgaggct agaggagttt acttctccct ctcgatggtc aggtcaggac 2220

tgtcatagac tccggatcac cttcctgtaa atgcttgctt tttgtgtgca gagagcctgt 2280

tttagctcgg gggtcctcag ctcactgagc tcgcggggca ggggtgggct cgggctggcg 2340

ccgcctgttc gggagcgcat ctccagcatg ctgtcgcaca gcttcgttgc taacaagacc 2400

gcttagtctc gtggttagac caacctgctt tctcgagtaa ttgttaattt acaggagttt 2460

cctgtatttt tcaacttata atcccctagt cagataactc tttaatcacc tattctgccc 2520

cttcattttc tccctatcga tctcagcaac ccatcactgc cctcactgtc cttaaactgt 2580

cccttaactg accagactgt ccctcagtgt cccctcagag tcacctccct atcacctcac 2640

tgtccctctc tgcccctctc tgcccctctc tgtccctccc tgcccctccc cgtcccctct 2700

ctgtccctct ctgcccctca ctgctcctct ctgcacctca ctgctcctca ctgccctggg 2760

ggaggcccgc atcgaggtgt ctctgctcac cccgtccccc accccgtacc ccccgccagg 2820

tgaagtggat cttctcctcg gt 2842

<210> SEQ ID NO 9
<211> LENGTH: 2840
<212> TYPE: DNA
<213> ORGANISM: sheep

<400> SEQUENCE: 9

cctacgcgtg tgtggtgatg cacgaggctc tgcacaacca ctacacacag aagtcggtct 60

ctaagcctcc gggtaaatga gccacacgcc cccgcaccag caagccctca cccagcccgc 120

cctccccggg ctccaggtcc agccaggacg ccctagcccc tccctgtgtg catgcctcct 180

gggccgccat gaataaagca cccaggccgc cctgggaccc tgcagcgctg tgctggttct 240

ttccgaggca gagccctggt gatcgccagg cctgcggggg gcgggctgag cccactctgg 300

gccgcttggt tcagcatctg tgggggcgct gacccctctc cgggccagac acacagtgag 360

tgggtccggc agggcacctg ggggctgccc gaggcctcgg aggggcttgg ccagaggcgc 420

agctccacgg ccccctccag ccaccacatt ctgggccaga ctctgggcag gaacgggga 480

agcccccgac acctcaggga ttgaggccca acgcttcccg cctctgctcc agcccacgct 540

gaggggcagg gccgcggcct tgtccccagg cccctgttcc tgggtgccca gagtccgtgt 600

gtccactctg ggcctgcctg gagccagact ggcccagggg gaggccctgc ttcaccctca 660

ggctcccgag gtcaggcatc atcctcgtcg gccagtagct ctgcctggct ctctctgccc 720

ggggccaagc ctgtgtgccc atggggaggt cgtccctgtg cctgaaaagg gcccaggctg 780

-continued

ggagccctga acgtccaggg cagggaccta gctgctccct ggggacactg agcccagagc 840

cccagacacc aagccccagc cccgcacgca cacgagacag cccacaccca gcgtcctcca 900

cacccactca ggcgtccacc cgcacacaag catgcttcac ccccgtcaca cacccacatg 960

cctgcacaca ctcaggtctc acgctccggg acccatggag tgatcccacg ggcccagacc 1020

cagagctggg tctcatgagc cctccctgtg gacaccagct ggtccccatc ctccagcgcc 1080

cttgggctgc tcagtggccc tttcccacac tgaccacact gaccaggtca gacatccttc 1140

ctcgcctccc ctggggcacc cacgcccctc ccttgcaggc tgagaccccc cctcagcccc 1200

tcgtcctggc accctcaccc ctcgggcaca gggacacagc ccggcactgt ctgccctccc 1260

tctcggggac agagcccagg cacgtgtgct ctgctgagcc tcccggctcc aggcctggcc 1320

cccagggcag aggaggccag gaattgagcc tctgtcctgc ggggaggtgg ggtcagggcc 1380

ccagctcagg gcacagctca ggatgggagc aggaccccac aggccaggcc cagacagtgg 1440

ccagggctgg ggctggggct ggggcccaga gactgacctc aggtgacccc tgcccggccc 1500

atgggggatc acaccgccat cccccccgcc gcagagggag ccctgccccg aagccccgat 1560

ggccccgccc agccccccgt gggcagacac agcactgacc cccctccctg tgcagatctg 1620

ctgctggagg aggagagctg tgcggacgcc caggacgggg agctggacgg gctctggacg 1680

actatctcca tcttcatcac gctcttcctg ctcagcgtct gctacagtgc caccgtgacc 1740

ctcttcaagg tgggggccca ccctgctggg ccctcgggcc ccctctctgt ccccagggtc 1800

cccgcagagt ccctccctgc ccctcactgt ccctccctgt ccctctctgt ccctctctgt 1860

ccctctctgt ccctctctgt ccgctcattt tcccttcacc gtaagcttga gacagattgg 1920

ggtcatttca gagggcgtct gaagagtctc tgtgccgcac gcctcccttc atgtcagtgg 1980

ggagaattca gcaagggtgg agtgctgggt gagaaatgag gcttgcggcg ctcacgagca 2040

gtgatggggc actgctgctc cctgagacct gcgcggacac cgttttccat cgcaggagaa 2100

gcgggcaagg gaaaacgccc tcttggtctc tcttgagtaa atgtcgcgtt ttggtcatca 2160

gtccctcccc cagtgaggct agaggagttt acttctccct ctcgatggtc aggtcaggac 2220

tgtcatagac tccggatcac cttcctgtaa atgcttgctt tttgtgtgca gagcctgttt 2280

tagctcgggg gtcctcagct cactgagctc gcggggcagg ggtgggctcg ggctggcgcc 2340

gcctgttcgg gagcggcatc tccagctgct gtcgcacagc ttcgttgcta acaagaccgc 2400

ttagtctcgt ggttagacca acctgctttc tcgagtaatt gttaatttac aggagtttcc 2460

tgtatttttc aacttataat cccctagtca gataactctt taatcaccta ttctgcccct 2520

tcattttctc cctatcgatc tcagcaaccc atcactgccc tcactgtcct taaactgtcc 2580

cttaactgac cagactgtcc ctcagtgtcc cctcagagtc acctccctat cacctcactg 2640

tccctctctg cccctctctg cccctctctg tccctctctg tccctccccg tcccctctct 2700

gtccctctct gcccctcact gctcctctct gcacctcact gctcctcact gccctggggg 2760

aggcccgcat cgaggtgtct ctgctcaccc cgtcccccac cccgtccccc ccgccaggtg 2820

aagtggatct tctcctcggt 2840

<210> SEQ ID NO 10
<211> LENGTH: 3120
<212> TYPE: DNA
<213> ORGANISM: rabbit

-continued

<400> SEQUENCE: 10

ctccccccca cgccgcagct gtgcaccccg cacacaaata aagcacccag ctctgccctg 60

agaggctgtc ctgattcctt ccaaggcaga ggcttccact cgggccggac agggttgggc 120

gggcgccgtg ggctctgctg tggccagcag ccagaacggt caacagtggg acaggggcag 180

acccacagca caggggcctg ccaagaactg ggctcagccg gagtgctgtg gcaggtcccc 240

ccttgcagct agcacgtgtg tgctgggcag gcagaggccc ccaggggagg agcacacagc 300

taccacctct gcaagagcct ggcctggcgc ccaggtccca gtccacaggg tgtgtagtac 360

acagagcctc atcttaccac agatgtaggg acagacccac cacgcccctg caccccaccc 420

agcctcgccc cttgtgggac cagggctacc actccactcc cccgcccaga gcagcagaag 480

caggtggcat cctcagcaga gggacagtct cacccctcca cggcactgag ccctgaccca 540

tcaaacaagc ccctcctgct gcacagcacc tgtgtgcaca tcacacacac acacacacac 600

acactgaggc ctgaccccat caaacaagcc cctcctgctg cacagcacct gtgtgcacat 660

cacacacaca cacacacaca cactgaggcc tgaccccatc ctgccctcct gctgcatggc 720

acctgtgtgc acatcacaca cacatgcaca cacacactca cacacactga gccctgaccc 780

catcctgccc tcctgctgca tggcacctgt gtgcacatca cacacacaca cacacacaca 840

cacacactga gccctgaccc catcctgccc tcctgctgca tggcacctgt gcacacatca 900

caaacacgcc tgcctcatac actggcactc agaaggggcc cctgtacacg catacacatg 960

cacacacctt gacacatggg ccccctacac acgcatcaca cacactcatg cacactcctc 1020

acacatggcc ctcctgcaca tacattgcac acacatgtgc acagacctca caatgggccc 1080

ctgcacacac attgtacaca cgcatgtgca cacacttcac acatgggccc cctgcacatg 1140

cattgcacac acagacacac acatgtgcat tcctcacaca ttggggcctt gcaagggatg 1200

ccctgcacac acattgcaca tgctcacatg tgcacacacc ccacactgga gccttgcata 1260

gggcccccctg tacacacacc atgcatacac acacacctca cacaaggggc cccctacata 1320

cgcaaaacac acacacacac atgcacacac ctcatacacg ggcccccctac acacatcaca 1380

cacacacaca cacacacgta tgcatgcctc acacacagac cttgcaaggg gccccctgca 1440

catgcatcaa acacatatgc acatgtttca cacacacggt cccctacaca cactgcacac 1500

gcacacatgt gtacatgctt cacacactgg ggccttgcat ggggtcccct gcatagcata 1560

gcacccagag ccacgccagg tgcctgggca catggacact ggtgcacaca cagcacccaa 1620

gcccagctct cccatccaag gggcaccagc acccccccact cacgagcacc ctgaattcct 1680

gctccccaca agcgaacgtg caccctacct ctccagacgt ccctttcctg tggccactcc 1740

cataggtatt ggcgagaccc tcccttgacc cttgggcctg gtcacccagg ggacaggaga 1800

gggccaagtt gggccacagt accactgccc agcaggggtg aggcaagcag agggtgggtc 1860

tgtgaggcgt ctggccagcc gtgctggggc ccaggtgggg agcagctggg tggctgaggt 1920

ggcttccttg caggtggttg gggggagctg gccccacaag tgccactgcc cagcactgtc 1980

cagtgcttcc ccctgaacct cccggccacc catccccagc tgcagccgca gagggagtgc 2040

ccctcggcct cctcggcaag acgcacgctg actgcccctc cccatccaga gctgcagctg 2100

gacgagagct gtgccgaggc ccaggacggg gagctggacg ggctgtggac caccatcacc 2160

atcttcatct ccctcttcct gctcagcgtg tgctacagcg ccacagtcac cctcttcaag 2220

-continued

gtgggtgctg cacccggcac gggtgggctg ggggccaggg gcgggggccg ggggccaggc 2280

cctcctcacc ccgcgccgcc gctgctgcag gtgaagtgga tcttctcgtc cgtggtggag 2340

ctgaaacaca ccatcgctcc cgactacagg aacatgatcg ggcaggggggc ctaggccctt 2400

cgttctcaca gcctgcctcc ctggccagca ggagcccccg cctccgcctc ggaccccatg 2460

gctctctgct ctggccgctc cggacccctc cgcctcggga gaagcgcgca gctgatgcct 2520

gccggcccct ccacgcagca gtgcggacag cacgcatctg tcgtccaccc ggcaggaccc 2580

cacccagggc cagccctgac cgccagcctc ctggactcag ggctcctctg agaaaaggcc 2640

cacttgttgg tcccctcagc ccacacccag gcagcctccg gtgggtgctt ccctggaccc 2700

cagcctgagg cctatgcttg ttctcctgtg gctcttactc agaggcccgt gctggactcc 2760

cacccacagg gacagtgccc tgctccaacc ctcactgcac tgggggtcat ggggccacct 2820

tctgtgcagg ggtcctggct ccaaggagaa cactcgaagg gcctgcttgg ccacctggca 2880

ccacgggagc cccgctgggt agcttggcag ggacccctga gtagaggtgg gtgcacccag 2940

ccagaaagcc tgctggatgg acaggagcct ggcgtccggg ccccaggcag gcagacacgg 3000

cttcatggac aggagaggcc aaggaacatc agcaaagaga gacagctggg ccgggcgttc 3060

cagccagacc catcctgcag cccagcatcg gccccgtgta ctacagcagg gacagccagt 3120

<210> SEQ ID NO 11
<211> LENGTH: 2587
<212> TYPE: DNA
<213> ORGANISM: rabbit

<400> SEQUENCE: 11

gcgagacgcc tgccagggca ccgccagtga ccctgaggcc cagcctcgcc gctccctccc 60

ctcagtggac ccattcccac cacagtcctc cagcccctcc cctcccggcc ctcacccccc 120

ccttggcttt aaccttgcga atgttggtga gatggatgaa taaagtgaat ctttgcactt 180

gtgacttctc tctgcttctt catttaatgg ttattactca tggtttccca gttgccctaa 240

agtcaccgcc atttcatcct ccatcccacc ctgccctgct gtcctccggg agacaccact 300

ccctgaaacc cacaggcccc tgtcttcaca ccgccgaccc cgaccacacg tgaggggctt 360

gcttcgtgtc tcactccccc catcgagccc cagagtcctc ctttagtgtt cttacagtca 420

catacagtta tacagtttga gtcaatccaa cctgccctgc caatttccca aaacaaagat 480

tttcagaata aaacagctat gaagaaagtc atttatggaa gcatgatata caacaacaaa 540

acaatgcaaa caacctaact gaataagcag agggaaatgt tcagacacac tatggggctt 600

gggcttcatg gagtattaca ccttcattac atttttaaac ttgtattaag gagctcctat 660

attacaagga ttatactaga gcactttcca tgacctaatt aattctcatt acactgtgag 720

gttaaaagca ttagttaaaa tattgggcag gctccctata gccaacagtt gttcatattc 780

cataacccaa ccatcattta ggtgactcag ggtccttgtc caccaagaac tttggcaaga 840

atgttcagag caacttcctt tataaaagtc aaaaattgga agtaactcaa atgtctacca 900

acagtagaat gggctgttaa ttggcatatg tttacatatt agaatgctgt ttaataaaga 960

gaattaacaa actacaacta tccctaataa cataggtgac tcataaacat gatgttaagc 1020

acaagaaccc aaacacaaaa gacacactgt gtatgttttc atccatagga agttcaaaac 1080

tagttaaaaa ttgaattaga aattgagatg aagtttactc ttggctgggg gtgtggagtg 1140

-continued

aggcggtgcc tggtgggga cagaaagtgg ctgctggggt cttggtgatg ttctagtcct 1200

cactgtggtg tgtgctactc tgaaaatgta ttgagtacac aattaggttt tgtgctttca 1260

ttatactcca aagtaagttc tcataaacat tgccttacac ggggtctaca gataagagag 1320

actaagagga atgagtaaca gatcaaggcc acacagctgg taggcatggg cctgggatca 1380

aaccctgtct gcccaattct gctctcttga gccctacact attctttcca gcactggaat 1440

gccatgcaga acagggagta ggacatgcta cctccctagg gtctcctcct ttacccacct 1500

aaccaggagc acccatacat agaaacagga tggaaaagac catcagcaat ggaacaaggg 1560

agagattaac cttgttcagt attgtgatcc catgtaggaa agattgtggg aggagggctg 1620

cacacagagc accgtccccc ttctatgtgc ccaccgctct gtgccccctt atctgctcac 1680

ccgcccagcg tgcattcact cagcaccctt ttcgcctgcc ctctgaaaga ggtgcagaag 1740

taactaaacc agcttccctc cttcagtgac ttggaatcca gttttcctcc tctatttccc 1800

cctccttttc agtgcaggag cctggagaaa tgtgatttgt gttattataa atttcccaca 1860

tcattttgtg taagggaaaa tatactcaac agtcataact ggtaaaactg ctgtgaaaac 1920

taagagaagt aattcatgcg aaggttgagc accagccttg tatatactaa gagatccaga 1980

agtgttagtc accgttagaa ataagaagga gtagctcaat ttgactagtt cctggttcac 2040

tccttgaaca tgttcttcag ttatcatctt tcagtcccaa atgattgaac ttggaattaa 2100

ctcacatgga ttctagacct gtgccgagaa tggctgccac tcgtgctcta gagctctggg 2160

gatgaggctg tccctactgt ggtgtgctac aggtctaaca acacaccagg ttttgaagac 2220

ttagcactat gaatatatat atatattata ttccaataaa tttaacatac tttctacttt 2280

cattgcatgt tgagatagta atctactttg gatatatttg gttaaaccaa actattctca 2340

agacaaattt cataggttta tggtttttt acaatttaat caaaatataa acatagtcca 2400

aacaattaat ccatttaaag tggagaatgg cccaagtgtt tgggcccctg ctacccattt 2460

ttaagaccag atgttgctct tggcttctgg cttttgcttg gctcagccct ggccattgca 2520

gccatctgag gagtaaacag tggatggaag acatctcccc ccaccctgcc cataaagctc 2580

gggatcc 2587

<210> SEQ ID NO 12
<211> LENGTH: 1205
<212> TYPE: DNA
<213> ORGANISM: rabbit
<220> FEATURE:
<221> NAME/KEY: Unsure
<222> LOCATION: (997)
<223> OTHER INFORMATION: n at position 997 is uncertain
<220> FEATURE:
<221> NAME/KEY: Unsure
<222> LOCATION: (1127)
<223> OTHER INFORMATION: n at position 1127 is uncertain

<400> SEQUENCE: 12

cttcagcgtg aaccacgccc tcccgctgag tctcacgcac ccccggtgca ggcagtccgg 60

cctcacctgg aaggtgcact gactgaagac actgcaaggg gtgagagcat ttctcaggaa 120

agagccctga gtttagaagg ccagagagca gagggctgag ggctgccttg cgctgcaacc 180

catggaaaca caggcttagc agatgttcaa gctccgggag tccacactgg gtgagggcag 240

gcgtccagcc tgacatggcc cccacagact cgcccacagg tgacgccaga tgaggacggt 300

-continued

caaggatcgg gggatcctac atgcccaggg gcaccaagac agccaggaga gcaccagagg 360

ccacaagaga ggcctgggac agtctccctg ctgacatcca gagcccaggc cccacttggc 420

agagctggct gagaacacgt ctctgcggtg gaagctgccc cgtcctgggt gttgctcggc 480

gggctaagcc gactgacgcg gggcgggcca ggccatcggc cccacggcct gcagcttcct 540

ccccagccca ggccacgtgg gctcctggct gaactggccg ctcgctgagc tctcaccccc 600

ccacccagca gcaggccggg cggtgctgcc atgagctcca ttcccaccac acaagcgaca 660

gcccgggcag cgccccaggc ccacggggcg tttgctgtgc ggctcgcact cgctgctcag 720

ggccagcgca gggtgcagca gggactcacc aacccgcccc gactcggctg gcacgtttac 780

tggaggcctc tgagcctgac cgtggcagtg gggcccgagc aggctccagg ctgccccctg 840

caccctgggc ttgccgctcc gggacccctg gtgggcacct tcccagatgt gctcccaccg 900

tgcctccttg gggctctggg ctcatagcgg tcactctccg ccttctctcc tcccagccct 960

ttcctgcctc cctatggccc catctagctc tgccctntct agagcctcta cctggaagga 1020

atctgctgtt ggaccaagac accacccgca gcacaggtgg gcgccttgca ctgtgctagg 1080

ccctccccgc acagaaaagg gccctaggct ctggaggctg ctgctgnctc tggggctggc 1140

atcgggcgca ccctgcaccc tgcaccctga ggaaactcag gcctgcccgc tccaggcctg 1200

tccct 1205

<210> SEQ ID NO 13
<211> LENGTH: 668
<212> TYPE: DNA
<213> ORGANISM: rabbit

<400> SEQUENCE: 13

gaagctttac ttgttggggg cgggcaggtc taagggacct gccaggtgtg ggggctgggc 60

ttgactcagc aggagccttc tagaaggaaa gctctggaga aggtgggggc agagggcggg 120

aaaggcctgt gaggaggcgg gtggtgggca gggccactgg gaagggaggg ctgggggtga 180

cactcaggtt ggcactgggg aggacctgag gaggcaggtg ccaggcacag agctgaacct 240

gggcagggca ggggcaggta acaagaagga ttctccttgg agcctggtcc agggtggtcc 300

agggcggtcc agggcctggg gtttgcaagc tgggctgtga cagggcctct ctccccaggg 360

gcaagcagca aagcctgggc acagagccca aagcccccac acagagaagc tccccagggc 420

agggcctgca gggcttgggg gaccttcttg gagcaggcag aggacagagg catgagatca 480

gcctcccaga ggctggaatg ataggtccag caggaggggc ccacatgggc tctggttagc 540

aggagaaaac agcccccagg tccccatggc caccacgcac cgactgctgg tgaagctttg 600

ggtggcagac gagagccaca tggcagctgc tcctgtcact ctctgggagt gcatcgaggg 660

gcgtcgac 668

<210> SEQ ID NO 14
<211> LENGTH: 45
<212> TYPE: PRT
<213> ORGANISM: camel

<400> SEQUENCE: 14

Glu Pro Leu Leu Glu Glu Glu Ser Cys Ala Glu Ala Gln Ser Gly Glu
1 5 10 15

Leu Asp Gly Leu Trp Thr Thr Ile Ser Ile Phe Ile Thr Leu Phe Leu

-continued

```
            20                  25                  30

Leu Ser Val Cys Tyr Ser Ala Thr Val Thr Leu Phe Lys
         35                  40                  45


<210> SEQ ID NO 15
<211> LENGTH: 44
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 15

Glu Leu Gln Leu Glu Glu Ser Cys Ala Glu Ala Gln Asp Gly Glu Leu
  1               5                  10                  15

Asp Gly Leu Trp Thr Thr Ile Thr Ile Phe Ile Thr Leu Phe Leu Leu
            20                  25                  30

Ser Val Cys Tyr Ser Ala Thr Val Thr Phe Phe Lys
         35                  40


<210> SEQ ID NO 16
<211> LENGTH: 44
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 16

Glu Leu Gln Leu Glu Glu Ser Cys Ala Glu Ala Gln Asp Gly Glu Leu
  1               5                  10                  15

Asp Gly Leu Trp Thr Thr Ile Thr Ile Leu Ile Thr Leu Phe Leu Leu
            20                  25                  30

Ser Val Cys Tyr Ser Ala Thr Val Thr Phe Phe Lys
         35                  40


<210> SEQ ID NO 17
<211> LENGTH: 44
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 17

Glu Leu Gln Leu Glu Glu Ser Cys Ala Glu Ala Gln Asp Gly Glu Leu
  1               5                  10                  15

Asp Gly Leu Trp Thr Thr Ile Thr Ile Phe Ile Thr Leu Phe Leu Leu
            20                  25                  30

Ser Val Cys Tyr Ser Ala Thr Val Thr Phe Phe Lys
         35                  40


<210> SEQ ID NO 18
<211> LENGTH: 44
<212> TYPE: PRT
<213> ORGANISM: mouse

<400> SEQUENCE: 18

Gly Leu Gln Leu Asp Glu Thr Cys Ala Glu Ala Gln Asp Gly Glu Leu
  1               5                  10                  15

Asp Gly Leu Trp Thr Thr Ile Thr Ile Phe Ile Ser Leu Phe Leu Leu
            20                  25                  30

Ser Val Cys Tyr Ser Ala Ala Val Thr Leu Phe Lys
         35                  40


<210> SEQ ID NO 19
<211> LENGTH: 44
```

-continued

<212> TYPE: PRT
<213> ORGANISM: mouse

<400> SEQUENCE: 19

Gly Leu Asp Leu Asp Asp Val Cys Ala Glu Ala Gln Asp Gly Glu Leu
1 5 10 15

Asp Gly Leu Trp Thr Thr Ile Thr Ile Phe Ile Ser Leu Phe Leu Leu
20 25 30

Ser Val Cys Tyr Ser Ala Ser Val Thr Leu Phe Lys
35 40

<210> SEQ ID NO 20
<211> LENGTH: 45
<212> TYPE: PRT
<213> ORGANISM: mouse

<400> SEQUENCE: 20

Pro Gly Leu Gln Leu Asp Glu Thr Cys Ala Glu Ala Gln Asp Gly Glu
1 5 10 15

Leu Asp Gly Leu Trp Thr Thr Ile Thr Ile Phe Ile Ser Leu Phe Leu
20 25 30

Leu Ser Val Cys Tyr Ser Ala Ala Val Thr Leu Phe Lys
35 40 45

<210> SEQ ID NO 21
<211> LENGTH: 44
<212> TYPE: PRT
<213> ORGANISM: mouse

<400> SEQUENCE: 21

Glu Leu Glu Leu Asn Glu Thr Cys Ala Glu Ala Gln Asp Gly Glu Leu
1 5 10 15

Asp Gly Leu Trp Thr Thr Ile Thr Ile Phe Ile Ser Leu Phe Leu Leu
20 25 30

Ser Val Cys Tyr Ser Ala Ser Val Thr Leu Phe Lys
35 40

<210> SEQ ID NO 22
<211> LENGTH: 44
<212> TYPE: PRT
<213> ORGANISM: mouse

<400> SEQUENCE: 22

Glu Leu Glu Leu Asn Gly Thr Cys Ala Glu Ala Gln Asp Gly Glu Leu
1 5 10 15

Asp Gly Leu Trp Thr Thr Ile Thr Ile Phe Ile Ser Leu Phe Leu Leu
20 25 30

Ser Val Cys Tyr Ser Ala Ser Val Thr Leu Phe Lys
35 40

<210> SEQ ID NO 23
<211> LENGTH: 44
<212> TYPE: PRT
<213> ORGANISM: sheep

<400> SEQUENCE: 23

Leu Leu Leu Glu Glu Glu Ser Cys Ala Asp Ala Gln Asp Gly Glu Leu
1 5 10 15

-continued

Asp Gly Leu Trp Thr Thr Ile Ser Ile Phe Ile Thr Pro Phe Leu Leu
20 25 30

Ser Val Cys Tyr Ser Ala Thr Val Thr Leu Phe Lys
35 40

<210> SEQ ID NO 24
<211> LENGTH: 44
<212> TYPE: PRT
<213> ORGANISM: sheep

<400> SEQUENCE: 24

Leu Leu Leu Glu Glu Glu Ser Cys Ala Asp Ala Gln Asp Gly Glu Leu
1 5 10 15

Asp Gly Leu Trp Thr Thr Ile Ser Ile Phe Ile Thr Leu Phe Leu Leu
20 25 30

Ser Val Cys Tyr Ser Ala Thr Val Thr Leu Phe Lys
35 40

<210> SEQ ID NO 25
<211> LENGTH: 19
<212> TYPE: PRT
<213> ORGANISM: cow

<400> SEQUENCE: 25

Leu Leu Leu Glu Glu Glu Ile Cys Ala Asp Asp Leu Asp Gly Glu Leu
1 5 10 15

Asp Gly Leu

<210> SEQ ID NO 26
<211> LENGTH: 19
<212> TYPE: PRT
<213> ORGANISM: cow

<400> SEQUENCE: 26

Leu Leu Leu Glu Glu Glu Ile Cys Ala Asp Ala Gln Asp Gly Glu Leu
1 5 10 15

Asp Gly Leu

<210> SEQ ID NO 27
<211> LENGTH: 43
<212> TYPE: PRT
<213> ORGANISM: rabbit

<400> SEQUENCE: 27

Leu Gln Leu Asp Glu Ser Cys Ala Glu Ala Gln Asp Gly Glu Leu Asp
1 5 10 15

Gly Leu Trp Thr Thr Ile Thr Ile Phe Ile Ser Leu Phe Leu Leu Ser
20 25 30

Val Cys Tyr Ser Ala Thr Val Thr Leu Phe Lys
35 40

<210> SEQ ID NO 28
<211> LENGTH: 27
<212> TYPE: PRT
<213> ORGANISM: camel

<400> SEQUENCE: 28

Val Lys Trp Ile Phe Ser Ser Val Val Glu Leu Lys Arg Thr Ile Val
1 5 10 15

-continued

```
Pro Asp Tyr Arg Asn Met Ile Gly Gln Gly Ser
            20                  25


<210> SEQ ID NO 29
<211> LENGTH: 27
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 29

Val Lys Trp Ile Phe Ser Ser Val Val Asp Leu Lys Gln Thr Ile Ile
  1               5                  10                  15

Pro Asp Tyr Arg Asn Met Ile Gly Gln Gly Ala
            20                  25


<210> SEQ ID NO 30
<211> LENGTH: 27
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 30

Val Lys Trp Ile Phe Ser Ser Val Val Asp Leu Lys Gln Thr Ile Ile
  1               5                  10                  15

Pro Asp Tyr Arg Asn Met Ile Gly Gln Gly Ala
            20                  25


<210> SEQ ID NO 31
<211> LENGTH: 27
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 31

Val Lys Trp Ile Phe Ser Ser Val Val Asp Leu Lys Gln Thr Ile Ile
  1               5                  10                  15

Pro Asp Tyr Arg Asn Met Ile Gly Gln Gly Ala
            20                  25


<210> SEQ ID NO 32
<211> LENGTH: 27
<212> TYPE: PRT
<213> ORGANISM: mouse

<400> SEQUENCE: 32

Val Lys Trp Ile Phe Ser Ser Val Val Glu Leu Lys Gln Thr Leu Val
  1               5                  10                  15

Pro Glu Tyr Lys Asn Met Ile Gly Gln Ala Pro
            20                  25


<210> SEQ ID NO 33
<211> LENGTH: 27
<212> TYPE: PRT
<213> ORGANISM: mouse

<400> SEQUENCE: 33

Val Lys Trp Ile Phe Ser Ser Val Val Glu Leu Lys Gln Thr Ile Ser
  1               5                  10                  15

Pro Asp Tyr Arg Asn Met Ile Gly Gln Gly Ala
            20                  25


<210> SEQ ID NO 34
```

-continued

<211> LENGTH: 27
<212> TYPE: PRT
<213> ORGANISM: mouse

<400> SEQUENCE: 34

Val Lys Trp Ile Phe Ser Ser Val Val Glu Leu Lys Gln Thr Leu Val
1 5 10 15

Pro Glu Tyr Lys Asn Met Ile Gly Gln Ala Pro
20 25

<210> SEQ ID NO 35
<211> LENGTH: 27
<212> TYPE: PRT
<213> ORGANISM: mouse

<400> SEQUENCE: 35

Val Lys Trp Ile Phe Ser Ser Val Val Gln Val Lys Gln Thr Ala Ile
1 5 10 15

Pro Asp Tyr Arg Asn Met Ile Gly Gln Gly Ala
20 25

<210> SEQ ID NO 36
<211> LENGTH: 27
<212> TYPE: PRT
<213> ORGANISM: mouse

<400> SEQUENCE: 36

Val Lys Trp Ile Phe Ser Ser Val Val Gln Val Lys Gln Thr Ala Ile
1 5 10 15

Pro Asp Tyr Arg Asn Met Ile Gly Gln Gly Ala
20 25

<210> SEQ ID NO 37
<211> LENGTH: 27
<212> TYPE: PRT
<213> ORGANISM: rabbit

<400> SEQUENCE: 37

Val Lys Trp Ile Phe Ser Ser Val Val Glu Leu Lys His Thr Ile Ala
1 5 10 15

Pro Asp Tyr Arg Asn Met Met Gly Gln Gly Ala
20 25

<210> SEQ ID NO 38
<211> LENGTH: 8
<212> TYPE: PRT
<213> ORGANISM: sheep

<400> SEQUENCE: 38

Val Lys Trp Ile Phe Ser Ser Val
1 5

<210> SEQ ID NO 39
<211> LENGTH: 29
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:primer

<400> SEQUENCE: 39

cgcaagcttc ctacacgtgt gtggtgatg 29

-continued

<210> SEQ ID NO 40
<211> LENGTH: 28
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:primer

<400> SEQUENCE: 40

gtcgacgccc ctcgatgcac tcccagag 28

<210> SEQ ID NO 41
<211> LENGTH: 29
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:primer

<400> SEQUENCE: 41

ggtaccctct ccctccccca cgccgcagc 29

<210> SEQ ID NO 42
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:primer

<400> SEQUENCE: 42

atatctcaga actggctgtc cctgctgtag tacacgg 37

<210> SEQ ID NO 43
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:primer

<400> SEQUENCE: 43

gtcgacactg gacgctgaac ctcgcgg 27

<210> SEQ ID NO 44
<211> LENGTH: 28
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:primer

<400> SEQUENCE: 44

ggtaccgggg gcttgccggc cgtcgcac 28

<210> SEQ ID NO 45
<211> LENGTH: 38
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:primer

<400> SEQUENCE: 45

gcggccgctg gcgaggagac caagctggag atcaaacg 38

<210> SEQ ID NO 46
<211> LENGTH: 36

-continued

<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:primer

<400> SEQUENCE: 46

gtcgacgcag cccaaagctg ttgcaatggg gcagcg 36

<210> SEQ ID NO 47
<211> LENGTH: 35
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:primer

<400> SEQUENCE: 47

atatggtacc gcgagacgcc tgccagggca ccgcc 35

<210> SEQ ID NO 48
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:primer

<400> SEQUENCE: 48

ggatcccgag ctttatgggc agggtggggg 30

<210> SEQ ID NO 49
<211> LENGTH: 42
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:primer

<400> SEQUENCE: 49

atatgtcgac ctgggataag catgctgttt tctgtctgtc cc 42

<210> SEQ ID NO 50
<211> LENGTH: 31
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:primer

<400> SEQUENCE: 50

ctaggtacca gcaggtgggg gcacttctcc c 31

<210> SEQ ID NO 51
<211> LENGTH: 1719
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:human
immunoglobulin heavy chain C?1 gene segment
flanked by nucleotides derived from the rabbit
heavy chain.

<400> SEQUENCE: 51

tgacctacct accctgccaa ggtcaggggt cctccaaggc aagggatcac atggcaccac 60

ctctcttgca gcctccacca agggcccatc ggtcttcccc ctggcaccct cctccaagag 120

cacctctggg ggcacagcgg ccctgggctg cctggtcaag gactacttcc ccgaaccggt 180

-continued

gacggtgtcg tggaactcag gcgccctgac cagcggcgtg cacaccttcc cggctgtcct 240

acagtcctca ggactctact ccctcagcag cgtggtgacc gtgccctcca gcagcttggg 300

cacccagacc tacatctgca acgtgaatca caagcccagc aacaccaagg tggacaagaa 360

agttggtgag aggccagcac agggagggag ggtgtctgct ggaagccagg ctcagcgctc 420

ctgcctggac gcatcccggc tatgcagccc cagtccaggg cagcaaggca ggccccgtct 480

gcctcttcac ccggaggcct ctgcccgccc cactcatgct cagggagagg gtcttctggc 540

tttttcccca ggctctgggc aggcacaggc taggtgcccc taacccaggc cctgcacaca 600

aaggggcagg tgctgggctc agacctgcca gagccatat ccgggaggac cctgcccctg 660

acctaagccc accccaaagg ccaaactctc cactccctca gctcggacac cttctctcct 720

cccagattcc agtaactccc aatcttctct ctgcagagcc caaatcttgt gacaaaactc 780

acacatgccc accgtgccca ggtaagccag cccaggcctc gccctccagc tcaaggcggg 840

acaggtgccc tagagtagcc tgcatccagg gacaggcccc agccgggtgc tgacacgtcc 900

acctccatct cttcctcagc acctgaactc ctgggggggac cgtcagtctt cctcttcccc 960

ccaaaaccca aggacaccct catgatctcc cggacccctg aggtcacatg cgtggtggtg 1020

gacgtgagcc acgaagaccc tgaggtcaag ttcaactggt acgtggacgg cgtggaggtg 1080

cataatgcca agacaaagcc gcgggaggag cagtacaaca gcacgtaccg tgtggtcagc 1140

gtcctcaccg tcctgcacca ggactggctg aatggcaagg agtacaagtg caaggtctcc 1200

aacaaagccc tcccagcccc catcgagaaa accatctcca aagccaaagg tgggacccgt 1260

ggggtgcgag ggccacatgg acagaggccg gctcggccca ccctctgccc tgagagtgac 1320

cgctgtacca acctctgtcc ctacagggca gccccgagaa ccacaggtgt acaccctgcc 1380

cccatcccgg gatgagctga ccaagaacca ggtcagcctg acctgcctgg tcaaaggctt 1440

ctatcccagc gacatcgccg tggagtggga gagcaatggg cagccggaga acaactacaa 1500

gaccacgcct cccgtgctgg actccgacgg ctccttcttc ctctacagca agctcaccgt 1560

ggacaagagc aggtggcagc aggggaacgt cttctcatgc tccgtgatgc atgaggctct 1620

gcacaaccac tacacgcaga agagcctctc cctgtctccg ggtaaatgag cgctgtgccg 1680

gcgagctgcc cctctccctc ccccccacgc cgcagctgt 1719

<210> SEQ ID NO 52
<211> LENGTH: 390
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:a VH gene segment encoding a human VH element polypeptide sequence, with flanking sequences derived from rabbit immunoglobulin DNA sequences.

<400> SEQUENCE: 52

tgagtgacag tgtcctgacc atgtcgtctg tgtttgcagg tgtccagtgt gaggtgcagc 60

tgttggagtc cgggggaggt ctcgtccagc caggggggac cctgagactc acctgcgcag 120

tctctggatt caccttcagt agctatgcaa tgagctgggt ccgccaggct ccagggaagg 180

ggctggaatg ggtcggagcc attagtggta gtggtagcac atactacgcg gacagcgtga 240

aaggccgatt caccatctcc agagacaact ccaagaacac gctgtatctg caaatgaaca 300

gtctgagagc cgaggacacg gccgcctatt actgtgcgaa agacacagtg aggggccctc 360

-continued

aggctgagcc cagacacaaa cctccctgca 390

<210> SEQ ID NO 53
<211> LENGTH: 445
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:containing a human immunoglobulin light chain C??gene segment flanked by 50 nuleotides derived from the rabbit light chain immunoglobulin Kappal gene.

<400> SEQUENCE: 53

catccacatg gcacccaggg gagatgtcca ctggtaccta agcctcgcca tcctgtttgc 60

ttctttcctc aggaactgtg gctgcaccat ctgtcttcat cttcccgcca tctgatgagc 120

agttgaaatc tggaactgcc tctgttgtgt gcctgctgaa taacttctat cccagagagg 180

ccaaagtaca gtggaaggtg gataacgccc tccaatcggg taactcccag gagagtgtca 240

cagagcagga cagcaaggac agcacctaca gcctcagcag caccctgacg ctgagcaaag 300

cagactacga gaaacacaaa gtctacgcct gcgaagtcac ccatcagggc ctgagctcgc 360

ccgtcacaaa gagcttcaac aggggagagt gttagagcga gacgcctgcc agggcaccgc 420

cagcgaccct gaggcccagc ctcgc 445

<210> SEQ ID NO 54
<211> LENGTH: 632
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:a V??gene segment encoding a human V??element polypeptide sequence, flanking by sequences derived from rabbit immunoglobulin DNA.

<400> SEQUENCE: 54

ggcaggctgc tcccacccca tgcaggaggc agtaccaggc aggacccagc atggacatga 60

gggtccctgc tcagctcctg ggactcctgc tgctctggct cccaggtaag gagggaaaca 120

acaaaaattt tattcagcca gtgtagccac taatgcctgg cacttcagga aattcttctt 180

agaacattac taatcatgtg gatatgtgtt tttatgttcc taatatcaga taccagatgt 240

tacatccaga tgacccagtc tccatcctct ctgtctgcat ctgtgggaga cagagtcacc 300

atcacttgcc gagccagtca gggcattagc aattacttag cctggtatca gcagaaacca 360

gggaaggttc ccaagctcct gatttatgct gcatccactt tgcaatctgg ggtcccatcg 420

cggttcagtg gcagtggatc tgggacagat ttcactctta ccatcagcag cctgcagcct 480

gaagatgttg ccacctatta ctgtcaaaag tacaacagtg cccctccact tttcggcgga 540

gggaccaagg tggagatcaa acgtaagtgc actttcctaa tgttcctcac cgtttctgcc 600

tgatttgttt gctttttcca ttttttcgct at 632

<210> SEQ ID NO 55
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:primer

<400> SEQUENCE: 55

-continued

catacacagc catacatacg cgtgtggccg ctctgcctct ctcttgcagg tatggacagc 60

aagcgaaccg 70

<210> SEQ ID NO 56
<211> LENGTH: 71
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:primer

<400> SEQUENCE: 56

atcagggtga cccctacgtt acactcctgt caccaaggag tgggagggac tcagaagaac 60

tcgtcaagaa g 71

<210> SEQ ID NO 57
<211> LENGTH: 419
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:a gene encoding human immunoglobulin light chain constant region Clambda2 flanked by nucleotides derived from the chicken light chain gene.

<400> SEQUENCE: 57

catacacagc catacatacg cgtgtggccg ctctgcctct ctcttgcagg tcagcccaag 60

gctgcccccc ccgtcactct gttcccgccc tcctctgagg agcttcaagc caacaaggcc 120

acactggtgt gtctcataag tgacttctac ccgggagccg tgacagtggc ttggaaagca 180

gatagcagcc ccgtcaaggc gggagtggag accaccacac cctccaaaca aagcaacaac 240

aagtacgcgg ccagcagcta tctgagcctg acgcctgagc agtggaagtc ccacagaagc 300

tacagctgcc aggtcacgca tgaagggagc accgtggaga agacagtggc ccctacagaa 360

tgttcatagt agtcccactg gggatgcaat gtgaggacag tggttcctca ccctccctg 419

<210> SEQ ID NO 58
<211> LENGTH: 416
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:a VJ gene segment encoding a human VJ immunoglobulin polypeptide, with flanking sequences derived from chicken immunoglobulin DNA.

<400> SEQUENCE: 58

ttgccgtttt ctcccctctc tcctctccct ctccaggttc cctggtgcag tcagtgctga 60

ctcagccgcc ctcggtgtca gcagccccgg gacaagaagt cacgatctcc tgctccgggt 120

ctagtagcaa cattggcgat aatttcgtct cttggtacca gcagctgcct ggcactgccc 180

ctaagcttct gatctatgat aacaacaaga gaccctcggg catccctgac cgattctccg 240

gttccaaatc cggcacctca gccacattag gcatcactgg gctccaaacc ggcgacgagg 300

ctgactatta ctgtgggact tgggacagca gcctttctgt tggtatgttt gggggcggga 360

cacgcgtgac cgtcctaggt gagtcgctga cctcgtctcg gtctttcttc ccccat 416

What is claimed:

1. A humanized immunoglobulin molecule comprising at least a portion of a human immunoglobulin heavy chain constant (C) region, and variable region amino acids sequences encoded by more than one immunoglobulin variable (V) gene segment.

2. The humanized immunoglobulin molecule of claim 1 which is derived from a nonhuman transgenic animal relying primarily on gene conversion and/or somatic hypermutation to generate antibody diversity.

3. The humanized immunoglobulin molecule of claim 2 wherein said transgenic animal is a rabbit, chicken, sheep or cow.

4. The humanized immunoglobulin molecule of claim 1 wherein said human immunoglobulin heavy chain C region sequence is a C_γ, C_κ, or C_λ sequence.

5. The humanized immunoglobulin molecule of any one of claims **1-4**, which is specific for an antigen.

6. The humanized immunoglobulin molecule of claim 5, wherein said antigen is a microorganism selected from bacterium, fungus, or virus; an antigenic portion of said organism; an antigenic molecule derived from said microorganism; or a tumor-associated antigen.

7. The humanized immunoglobulin molecule of claim 6, wherein said bacterium is selected from *S. aureus, Pseudomonas aeruginosa, enterococcus, enterobacter*, and *Klebsiella pneumoniae.*

8. The humanized immunoglobulin molecule of claim 6, wherein said fungus is selected from *Candida albicans, Candida parapsilosis, Candida tropicalis*, and *Cryptococcus neoformans.*

9. The humanized immunoglobulin molecule of claim 6, wherein said virus is selected from respiratory synctial virus (RSV), Hepatitis C virus (HCV), Hepatitis virus (HBV), cytomegalovirus (CMV), EBV, and HSV.

10. The humanized immunoglobulin molecule of claim 6, wherein said antigen is selected from Her-2-neu antigen, CD20, CD22, CD53, prostate specific membrane antigen (PMSA), and 17-1A molecule.

11. A monoclonal antibody preparation comprising a humanized immunoglobulin molecule of claim 5.

12. A monoclonal antibody preparation comprising a humanized immunoglobulin molecule of any one of claims **6-10**.

13. The monoclonal antibody preparation of claim 11 which is substantially non-immunogenic to human.

14. The monoclonal antibody preparation of claim 12 which is substantially non-immunogenic to human.

15. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and the monoclonal antibody preparation of claim 11.

16. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and the monoclonal antibody preparation of claim 12.

17. A method of treating a disease in a human subject comprising administering to said subject a therapeutically effective amount of a pharmaceutical composition of claim 15.

18. The method of claim 17 wherein said disease is caused by bacterial, fungal or viral infection, or said disease is a cancer.

* * * * *